[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 21740
1. Feng L, Jia XB, Shi F, Chen Y: Identification of two polysaccharides from Prunella vulgaris L. and evaluation on their anti-lung adenocarcinoma activity. Molecules; 2010 Aug;15(8):5093-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of two polysaccharides from Prunella vulgaris L. and evaluation on their anti-lung adenocarcinoma activity.
  • In order to evaluate polysaccharide P32's anti-lung adenocarcinoma activities and immunomodulation effects, a C57BL/6 mouse-Lewis lung carcinoma (LLC) model was established and investigated.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714287.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Polysaccharides
  •  go-up   go-down


2. Wang CK, Chang H, Chen PH, Chang JT, Kuo YC, Ko JL, Lin P: Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. Int J Cancer; 2009 Aug 15;125(4):807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas.
  • We had previously reported that aryl hydrocarbon receptors (AhRs) are overexpressed in lung adenocarcinomas.
  • Benzo[a]pyrene (BaP), an AhR agonist, increased FGF-9 expression in human lung adenocarcinoma cells.
  • Similarly, several AhR agonists increased FGF-9 mRNA levels, and BaP-induced FGF-9 expression was prevented by cotreatment with AhR antagonist in human lung adenocarcinoma cells.
  • FGF-9 increased growth of lung fibroblasts but not that of lung adenocarcinoma cells.
  • However, conditioned media collected from FGF-9-treated fibroblasts increased cell growth of lung adenocarcinoma cells.
  • Furthermore, lung adenocarcinoma cells expressed FGF receptor 2 and cotreatment with anti-FGF receptor 2 prevented the interaction between fibroblasts and tumor cells.
  • It is likely that FGF-9-stimulated fibroblasts secreted unknown factors, which activated FGF receptor 2 and subsequently promoted growth of lung adenocarcinoma cells.
  • FGF-9 expression was more common in adenocarcinomas than in squamous cell carcinomas.
  • Furthermore, FGF-9 and AhR expression were well correlated in lung adenocarcinomas.
  • These results suggest that AhR expression correlated positively with FGF-9 expression in lung adenocarcinomas, which might promote tumor growth by modulating communication between tumor cells and fibroblasts.
  • Preventing AhR overexpression or disturbing FGF-9 function may reduce the development of lung adenocarcinomas. (c) 2009 UICC.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Aged. Aryl Hydrocarbon Hydroxylases. Basic Helix-Loop-Helix Transcription Factors. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Cell Communication. Cytochrome P-450 CYP1B1. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358281.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AHR protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / FGF9 protein, human; 0 / Fibroblast Growth Factor 9; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Aryl Hydrocarbon; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  •  go-up   go-down


3. Langat DK, Sue Platt J, Tawfik O, Fazleabas AT, Hunt JS: Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. J Reprod Immunol; 2006 Aug;71(1):75-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma.
  • Because isoform-specific expression of HLA-G in male reproductive organs has not been reported, we investigated HLA-G1, -G2, -G5, -G6 mRNAs and proteins in four-to-five samples of normal prostate glands, prostates with benign prostatic hyperplasia and prostate adenocarcinomas using RT-PCR and immunohistochemistry.
  • In prostatic adenocarcinomas, HLA-G5 protein was detectable mainly in the secretions.
  • In addition, normal cellular localization is disturbed in benign and malignant prostatic adenocarcinomas.
  • The results are consistent with this molecule may influencing female immune receptivity to sperm and suggest that such immunosuppression could be disturbed in men with prostatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. HLA Antigens / genetics. HLA Antigens / metabolism. Histocompatibility Antigens Class I / genetics. Histocompatibility Antigens Class I / metabolism. Leukocytes / metabolism. Prostate / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616377.001).
  • [ISSN] 0165-0378
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 33994-09; United States / NICHD NIH HHS / HD / P01 HD39878; United States / NCRR NIH HHS / RR / RR16475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / RNA, Messenger
  •  go-up   go-down


Advertisement
4. Levi GS, Harpaz N: Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol; 2006 Aug;30(8):1022-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease.
  • Chronic idiopathic inflammatory bowel disease (IBD) with extensive colonic involvement predisposes to the development of colorectal adenocarcinoma.
  • Among the types of cancer occurring in this setting is an unusually well-differentiated low-grade tubuloglandular adenocarcinoma (LGTGA) that has not been studied systematically thus far.
  • Twelve patients had ulcerative colitis, 4 Crohn disease, and 1 indeterminate colitis.
  • Twelve carcinomas (57%) with well-defined superficial regions of LGTGA progressed histologically to conventional adenocarcinoma in deeper regions.
  • Two adverse outcomes were attributable to synchronous advanced-stage conventional cancers and the third to progression from LGTGA to poorly differentiated adenocarcinoma.
  • Coexpression of CK7 and CK20 was conserved in regions of conventional adenocarcinoma derived from LGTGA.
  • Histologic progression from LGTGA to conventional types of adenocarcinoma parallels clinical progression to more aggressive neoplasia.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Inflammatory Bowel Diseases / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861975.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Pazos Y, Alvarez CJ, Camiña JP, Casanueva FF: Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. FEBS J; 2007 Nov;274(21):5714-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway.
  • The present study analyzes the molecular steps involved in the full lysophosphatidic acid (LPA) receptor-mediated activation of the mitogenic extracellular signal-regulated kinase (ERK) pathway and its consequent role as an inhibitor of ghrelin secretion in the gastric adenocarcinoma cell line AGS.
  • Finally, a correlation was observed between the mitogenic effects of LPA and ghrelin secretion in the human gastric adenocarcinoma cell line AGS.
  • [MeSH-major] Adenocarcinoma / metabolism. Ghrelin / metabolism. Lysophospholipids / pharmacology. MAP Kinase Signaling System. Stomach Neoplasms / metabolism


6. Maekawa S, Hishima T, Yamada Y, Ichikawa H, Natsui S, Shinohara M: [A case of primary urethral adenocarcinoma accompanied by vaginal wall infiltration in which the CA19-9 level was very high]. Hinyokika Kiyo; 2009 Aug;55(8):513-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary urethral adenocarcinoma accompanied by vaginal wall infiltration in which the CA19-9 level was very high].
  • Computed tomography confirmed a urethral tumor, and transurethral biopsy confirmed adenocarcinoma.
  • Based on the above findings, the patient was diagnosed as having primary urethral adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Urethral Neoplasms / pathology. Vagina / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / secondary. Vaginal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764540.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  • [Number-of-references] 11
  •  go-up   go-down


7. Prosvic P, Brod'ák M, Odrázka K, Morávek P: [A case of an asynchronic triple tumorous disorder: a rectal adenocarcinoma, a carcinoma of the kidney and a prostatic adenocarcinoma--case report]. Rozhl Chir; 2005 Jan;84(1):41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of an asynchronic triple tumorous disorder: a rectal adenocarcinoma, a carcinoma of the kidney and a prostatic adenocarcinoma--case report].
  • In the year 1980 in 56 years old patient had histologically proven rectal adenocarcinoma and consequently was done radical Miles amputation of rectum.
  • In December 1991 in the same patient was histologically proven well differentiated adenocarcinoma of prostate after transurethral resection of prostate.
  • The authors emphasize pertinence radical surgical access incuding multiplex malignant tumors and consider to carry out oncology screening in the all of patients with proven malignant tumor.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Renal Cell. Kidney Neoplasms. Neoplasms, Second Primary. Prostatic Neoplasms. Rectal Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813456.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


8. Koistinen H, Seppälä M, Nagy B, Tapper J, Knuutila S, Koistinen R: Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells. Am J Obstet Gynecol; 2005 Dec;193(6):1955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells.
  • We aimed to elucidate its role in growth and gene expression of endometrial adenocarcinoma cells, and hypothesized that glycodelin affects cell growth and tumor-associated gene expression.
  • STUDY DESIGN: Endometrial adenocarcinoma HEC-1B cells were transfected with glycodelin cDNA in both antisense and sense orientations.
  • RESULTS: Compared with native and antisense-transfected carcinoma cells, sense-transfected, glycodelin-producing carcinoma cells showed reduced proliferation, morphologic changes, and altered expression of cancer-related genes.
  • These results suggest a novel mechanism whereby malignant growth of endometrial adenocarcinoma cells is regulated.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Glycoproteins / physiology. Pregnancy Proteins / physiology
  • [MeSH-minor] Antigens / metabolism. Antigens, Neoplasm. Antisense Elements (Genetics). Cell Line, Tumor. Cell Proliferation. Down-Regulation / genetics. Female. Humans. Immunohistochemistry. Mucin-1. Mucins / metabolism. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Up-Regulation / genetics. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325596.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Antisense Elements (Genetics); 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / bcl-X Protein
  •  go-up   go-down


9. Houghton O, Jamison J, Wilson R, Carson J, McCluggage WG: p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology; 2010 Sep;57(3):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection.
  • AIMS: The association between human papillomavirus (HPV) and cervical carcinoma is well known, with HPV being identifiable in almost all cervical squamous carcinomas and most adenocarcinomas.
  • However, the prevalence of HPV in unusual morphological types of cervical adenocarcinoma has not been investigated extensively.
  • The aim was to determine HPV status in a series of primary cervical adenocarcinomas, enriched for unusual morphological types.
  • METHODS AND RESULTS: Sixty-three cervical adenocarcinomas, comprising those of usual type (n = 43), minimal deviation type (n = 4), gastric type (n = 3), intestinal type (n = 3), mesonephric type (n = 3), clear cell type (n = 4), serous type (n = 2) and hepatoid type (n = 1) underwent linear array HPV genotyping and immunohistochemistry for p16.
  • Seventy-eight per cent of usual-type adenocarcinomas were HPV-positive, as was the single serous carcinoma in which there was sufficient DNA for analysis.
  • In contrast, all minimal deviation adenocarcinomas and those of gastric, intestinal, mesonephric and clear cell types were HPV-negative, as was the single hepatoid carcinoma.
  • All usual-type adenocarcinomas exhibited p16 immunoreactivity (diffuse staining in all but one case), as did 11 of 20 of those of unusual morphological type (five focal, six diffuse).
  • CONCLUSIONS: Most, but not all, cervical adenocarcinomas of usual type contain HPV, but those of unusual morphological type are almost always HPV-negative.
  • This has implications for the efficacy of HPV vaccination in the prevention of cervical adenocarcinoma.
  • A significant proportion of cervical adenocarcinomas are p16-positive in the absence of HPV, illustrating that in these neoplasms diffuse p16 immunoreactivity is not a reliable surrogate marker of the presence of high-risk HPV.
  • [MeSH-major] Adenocarcinoma / virology. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20727021.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


10. De Las Heras M, Murcia P, Ortín A, Azúa J, Borderías L, Alvarez R, Jiménez-Más JA, Marchetti A, Palmarini M: Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses. Cancer Lett; 2007 Dec 8;258(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses.
  • A proportion of human lung adenocarcinomas (hLACs) express an antigen related to the major capsid protein (CA) of Jaagsiekte sheep retrovirus (JSRV), a Betaretrovirus that causes a transmissible lung cancer in sheep.
  • Results obtained indicate that JSRV is not associated with human lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / virology. Gene Products, gag / metabolism. Jaagsiekte sheep retrovirus / isolation & purification. Lung Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889995.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95706-01
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Gene Products, gag
  •  go-up   go-down


11. Jin G, Hu XG, Ying K, Tang Y, Liu R, Zhang YJ, Jing ZP, Xie Y, Mao YM: Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays. World J Gastroenterol; 2005 Nov 7;11(41):6543-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays.
  • AIM: To study the pathogenetic processes and the role of gene expression by microarray analyses in expediting our understanding of the molecular pathophysiology of pancreatic adenocarcinoma, and to identify the novel cancer-associated genes.
  • METHODS: Nine histologically defined pancreatic head adenocarcinoma specimens associated with clinical data were studied.
  • In pancreatic adenocarcinoma tissue, several invasion and metastasis related genes showed their high expression levels, suggesting that poor prognosis of pancreatic adenocarcinoma might have a solid molecular biological basis.
  • CONCLUSION: The application of cDNA microarray technique for analysis of gene expression patterns is a powerful strategy to identify novel cancer-associated genes, and to rapidly explore their role in clinical pancreatic adenocarcinoma.
  • Microarray profiles provide us new insights into the carcinogenesis and invasive process of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425432.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4355802
  •  go-up   go-down


12. Stipa F, Alessandroni L, Cimitan A, Burza A, Cavallotti C, Cavallini M, Tersigni R, Ziparo V: [Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head and papilla of Vater]. Minerva Chir; 2009 Aug;64(4):395-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head and papilla of Vater].
  • [Transliterated title] Duodenocefalopancreatectomia per adenocarcinoma della testa del pancreas e della papilla di Vater.
  • AIM: The authors report their consecutive experience in the surgical management of adenocarcinoma (ADC) of head of pancreas and papilla of Vater, in order to review the available literature.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648859.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 79
  •  go-up   go-down


13. Almeida JP, Couto Netto SD, Rocha RP, Pfuetzenreiter EG Jr, Dedivitis RA: The role of intraoperative frozen sections for thyroid nodules. Braz J Otorhinolaryngol; 2009 Mar-Apr;75(2):256-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: All patients who had thyroid surgery for nodular disease and previous USG-guided FNAB in 2006 were prospectively analyzed.
  • They underwent intraoperative FS evaluation, and the biopsy material was classified as benign, malignant or follicular neoplasm.
  • RESULTS: Under the FS, 54% of the nodules were benign, 30% were follicular neoplasms, and 16% were malignant.
  • All cases considered benign and malignant under the FS evaluation were confirmed through the histological 'paraffin' analysis.
  • Among the 42 cases classified as 'follicular neoplasm' under the FNAB, in 1 case the FS conclusion was for papillary carcinoma, in 3 cases as benign (all confirmed through the 'paraffin'); and 38 cases continued as 'follicular pattern', being 29 follicular adenomas and 9 carcinomas through the 'paraffin'.
  • CONCLUSION: The FS is only indicated when the FNAB reports 'follicular neoplasm'.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575113.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


14. Li X, Cai L, Liang M, Wang Y, Yang J, Zhao Y: ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec (Hoboken); 2008 May;291(5):593-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway.
  • The purpose of this study was to investigate the inhibitory tumor growth effects of ING4 on lung adenocarcinoma, and its mechanism, by ING4 cDNA transduction into A549 cells.
  • Furthermore, the expression level of ING4 in lung adenocarcinoma tissues was examined.
  • The expression of ING4 was markedly reduced in human lung adenocarcinoma tissues.
  • Thus, ING4 may play an inhibitory role on A549 cell proliferation and tumor growth in lung adenocarcinoma by up-regulation or down-regulation of cell proliferation-regulating proteins such as p27, cyclinD1, SKP2, and Cox2 by means of inactivation of Wnt-1/beta-catenin signaling.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Homeodomain Proteins / metabolism. Lung Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism. Wnt Proteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399550.001).
  • [ISSN] 1932-8486
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / S-Phase Kinase-Associated Proteins; 0 / Tumor Suppressor Proteins; 0 / Wnt Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


15. Wakatsuki T, Irisawa A, Takagi T, Koyama Y, Hoshi S, Takenoshita S, Abe M, Ohira H: Primary adenocarcinoma of the minor duodenal papilla. Yonsei Med J; 2008 Apr 30;49(2):333-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the minor duodenal papilla.
  • A biopsy specimen showed moderately differentiated adenocarcinoma.
  • For treatment, pylorus-preserving pancreatoduodenectomy was performed, and histological findings revealed a well-differentiated adenocarcinoma that originated in the minor duodenal papilla.
  • Primary adenocarcinoma of the minor duodenal papilla is extremely rare.
  • Our case is the first report of primary adenocarcinoma of the minor duodenal papilla at an early stage with no infiltration into muscularis propria of the duodenum and pancreas.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Nov;54(5):622 [11677480.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):270-3 [11818939.001]
  • [Cites] Pancreas. 2003 Jul;27(1):96-7 [12826909.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Arch Surg. 1985 Dec;120(12):1381-3 [2865941.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):232-5 [2885079.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):475-9 [15758929.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Gastroenterol Jpn. 1991 Jun;26(3):356-62 [1716233.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Hepatogastroenterology. 1994 Feb;41(1):73-8 [8175122.001]
  • [Cites] Gastrointest Endosc. 1998 Dec;48(6):634-6 [9852458.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):189-92 [10228789.001]
  • [Cites] Am J Gastroenterol. 1987 Nov;82(11):1169-71 [3673996.001]
  • (PMID = 18452274.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2615313
  •  go-up   go-down


16. Salehi Z, Mollasalehi H, Jelodar MH, Kazemi M, Zahmatkesh R: The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. Oncol Res; 2010;18(7):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran.
  • Hence, we assessed whether H. pylori infection is associated with the development of gastric adenocarcinoma in northern Iran.
  • Gastric biopsy specimens from 168 patients suffering from gastric adenocarcinoma, gastric ulcer, and non-ulcer dyspepsia were analyzed by means of the polymerase chain reaction. H. pylori was detected in the gastric mucosa of 34 (75.5%) gastric adenocarcinoma, 56 (88.8%) gastric ulcer, and 36 (60%) non-ulcer dyspepsia.
  • In patients with gastric adenocarcinoma, the cagA was less commonly found than those in noncancer patients (4/34 vs. 58/92, p < 0.05).
  • Our work suggests that although H. pylori infection is significantly associated with gastric adenocarcinoma in northern Iran, the cagA is not the dominant virulence in development of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377133.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


17. Kountourakis P, Ardavanis A, Mantzaris I, Mitsaka D, Rigatos G: Urachal mucinous adenocarcinoma: a case report. J BUON; 2007 Oct-Dec;12(4):547-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal mucinous adenocarcinoma: a case report.
  • Adenocarcinomas account for 0.5-2% of all bladder cancers.
  • Urachal carcinoma is a rare neoplasm which represents 0.01% of all cancers in adults and account for one third of bladder adenocarcinomas.
  • A 65-year-old white man with an urachal mucinous adenocarcinoma is reported.
  • He underwent a partial cystectomy and en block excision of the umbilical ligament and remains disease-free after one year.
  • The development of this rare neoplasm should not be clearly dissociated from multiple sclerosis, either aetiologically sharing an unidentified common causative factor or due to its treatment with mitoxantrone.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Urachus. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067216.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


18. Ujiki MB, Talamonti MS: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol; 2007 Aug;34(4):311-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the surgical management of pancreatic adenocarcinoma.
  • Despite these advances, morbidity and mortality after pancreaticoduodenectomy are not insignificant and the overall prognosis following resection for adenocarcinoma of the pancreas remains poor.
  • Improvements in endoscopic decompression of malignant biliary obstruction have decreased the need for palliative bypass operations and have focused current surgical issues on ways to improve clinical outcomes following potentially curative resections.
  • This article will attempt to describe current guidelines for the preoperative, intraoperative, and postoperative management of patients with localized pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674959.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


19. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia; 2006 Apr;8(4):279-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
  • The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31).
  • Adenomatous polyposis coli and axin, which are both negative regulators, remained unchanged.
  • Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1999 Nov-Dec;60(6):544-8 [10545724.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):285-302 [16012954.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6776-84 [10597286.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] J Med Invest. 2000 Feb;47(1-2):47-55 [10740979.001]
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3245-9 [11309273.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52 [11467451.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):328-37 [15893416.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4127-34 [11911306.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2015-27 [12174879.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844 [12504222.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):202-16 [12512043.001]
  • [Cites] J Pathol. 2003 Feb;199(2):185-90 [12533831.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:199-231 [12195027.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):586-92 [12566300.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5 [12642683.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):161-70 [12706873.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):328-35 [12791299.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97 [12849999.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1134-46 [15057752.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Trends Genet. 1993 Sep;9(9):317-21 [8236461.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):177-84 [7824270.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):431-6 [10201374.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):504-11 [10404062.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1253-6 [10523691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):132-41 [15893845.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • (PMID = 16756720.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC1600679
  •  go-up   go-down


20. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


21. Svatek RS, Karam JA, Rogers TE, Shulman MJ, Margulis V, Benaim EA: Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer Prostatic Dis; 2007;10(3):279-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens.
  • Their presence has been described in conjunction with the occurrence of prostatic adenocarcinoma (pCA).
  • pCA was diagnosed in 66 (81.5%) of 81 patients with crystalloids, 70 (69.3%) of 101 patients with high-grade prostatic intraepithelial neoplasia (HGPIN), and 32 (84.2%) of 38 patients with both HGPIN and crystalloids on biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Inclusion Bodies / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325718.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Chan KK, Ip P, Kwong P, Tam KF, Ngan HY: A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer; 2008 May-Jun;18(3):559-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix.
  • Clear cell adenocarcinoma of the cervix (CCAC) is an uncommon tumor.
  • No good treatment option has been reported for advanced disease, and the prognosis is generally poor.
  • Reassessment 6 months later showed no evidence of residual disease, and she remained disease free during a follow-up of 1 year.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Rare Diseases. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692092.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A: Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev; 2010 Nov;36 Suppl 3:S21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
  • The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs.
  • Up till now EGFR gene mutations, KRAS gene mutations and EML4-ALK fusion genes are the most widely recognized alterations involved in both the biology and the clinical management of lung adenocarcinoma.
  • We also provide a potential algorithm as a guide in the choice of the best treatment for patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Molecular Targeted Therapy / methods. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21129606.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


24. Bellizzi AM, Bloomston M, Zhou XP, Iwenofu OH, Frankel WL: The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl Immunohistochem Mol Morphol; 2010 Oct;18(5):442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis.
  • Earlier studies have demonstrated loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) function in some pancreatic ductal adenocarcinomas (PDAs).


25. Horvatić Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomić-Brzac H, Kulić A: Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr; 2006 Oct;118(19-20):601-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Both uPA and PAI-1 concentrations were significantly higher in malignant thyroid tumors (uPA=1.342 +/- 2.944 and PAI-1=17.615 +/- 31.933 ng/mg protein) than in normal tissue (uPA=0.002 +/- 0.009, P=0.011 and PAI-1=2.333 +/- 0.338 ng/mg protein, P=0.001) with positive correlation of the two proteins in the tumors.
  • The lowest values were in adenomas (uPA=0.013 +/- 0.025 and PAI-1=2.785 +/- 1.069 ng/mg protein) and the highest in anaplastic carcinomas (uPA=8.45 +/- 2.192 and PAI-1=94.65 +/- 59.468 ng/mg protein).
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4065-71 [8033138.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Cancer Control. 2000 May-Jun;7(3):240-5 [10832110.001]
  • [Cites] Eur J Cancer. 1980 Nov;16(11):1513-5 [6262087.001]
  • [Cites] Surgery. 1984 Dec;96(6):957-71 [6505969.001]
  • [Cites] Thyroid. 1999 Sep;9(9):913-9 [10524570.001]
  • [Cites] Am J Med. 1994 Nov;97(5):418-28 [7977430.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4629-36 [6458354.001]
  • [Cites] Eur J Cancer. 1979 Aug;15(8):1033-41 [510341.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):393-402 [15091208.001]
  • [Cites] Surgery. 2004 Sep;136(3):609-16 [15349109.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2527-30 [8168072.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):636-43 [10676647.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1746-51 [10206287.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):285-96 [9198168.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1049 [2572788.001]
  • [Cites] Surgery. 1987 Dec;102(6):1088-95 [3686348.001]
  • [Cites] Thyroid. 2004 Jun;14(6):453-8 [15242573.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):878-83 [9041148.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):241-6 [15538115.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Oncol Rep. 1995 Jul;2(4):525-8 [21597769.001]
  • [Cites] Cancer Control. 2000 May-Jun;7(3):229-39 [10832109.001]
  • [Cites] J Endocrinol. 2000 Nov;167(2):229-38 [11054636.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):487-92 [8697395.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4671-5 [8062262.001]
  • [Cites] Adv Cancer Res. 1985;44:139-266 [2930999.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):81-9 [8615674.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6539-48 [7987854.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):724-32 [9477106.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):361-70 [7114941.001]
  • [Cites] Wien Klin Wochenschr. 1990 Apr 27;102(9):249-53 [2375111.001]
  • (PMID = 17136335.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / urokinase inhibitor; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


26. Kambhampati S, Banerjee S, Dhar K, Mehta S, Haque I, Dhar G, Majumder M, Ray G, Vanveldhuizen PJ, Banerjee SK: 2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the beta-catenin-E-cadherin axis. Mol Cancer Ther; 2010 Mar;9(3):523-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the beta-catenin-E-cadherin axis.
  • The purpose of this study was to evaluate whether 2-methoxyestradiol (2-ME(2)), a promising anticancer agent, modulates Barrett's esophageal adenocarcinoma (BEAC) cell growth and behavior through a cellular pathway involving beta-catenin in partnership with E-cadherin, which seems to play a critical role in the induction of antitumor responses in cancer cells.
  • The evidence presented points out that the effect of 2-ME(2) on beta-catenin-orchestrated signal transduction plausibly plays a multifaceted functional role to inhibit the proliferation and cell migration of 2-ME(2)-treated malignant cells and it could be a potential candidate in novel treatment strategies for Barrett's esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Sep;11(9):805-13 [9758359.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):639-46 [10493943.001]
  • [Cites] J Surg Res. 2005 Feb;123(2):302-11 [15680394.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14773-9 [15708859.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6625-33 [16166441.001]
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):116-23 [16231374.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):169-90 [16299787.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):230-8 [16299790.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):49-64 [16356831.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):284-91 [16428034.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):22-7 [16357512.001]
  • [Cites] Biochemistry. 2006 Mar 21;45(11):3703-13 [16533053.001]
  • [Cites] Biochemistry. 2006 Sep 5;45(35):10698-709 [16939222.001]
  • [Cites] Mol Carcinog. 2006 Nov;45(11):871-80 [16847823.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):41-8 [16969706.001]
  • [Cites] N Engl J Med. 2008 Apr 10;358(15):1634-5; author reply 1636 [18403774.001]
  • [Cites] Food Chem Toxicol. 2008 Jun;46(6):2042-53 [18331776.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4580-7 [18559502.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3509-23 [11029052.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1049-60 [11381089.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):363-75 [12726862.001]
  • [Cites] Blood. 2003 Jul 1;102(1):289-96 [12637335.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1067-75 [12807754.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2844-60 [12857869.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32544-51 [12805378.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):229-37 [12949799.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):128-35 [14653412.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):417-26 [14670179.001]
  • [Cites] Drug Resist Updat. 2003 Dec;6(6):355-61 [14744499.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):477-87 [15349822.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1615-20 [3102047.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3964-8 [8171020.001]
  • [Cites] Am J Gastroenterol. 1995 Oct;90(10):1808-13 [7572899.001]
  • [Cites] Toxicol Lett. 1995 Dec;82-83:155-8 [8597045.001]
  • [Cites] J Cell Biol. 1996 Mar;132(6):1105-14 [8601588.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):445-54 [8954717.001]
  • [Cites] Eur J Neurosci. 1997 Aug;9(8):1763-72 [9283831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • (PMID = 20197389.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1P20 RR15563; United States / NCRR NIH HHS / RR / P20 RR015563-10; United States / NCI NIH HHS / CA / CA87680; United States / NCRR NIH HHS / RR / P20 RR015563; United States / NCI NIH HHS / CA / R01 CA087680
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / beta Catenin; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  • [Other-IDs] NLM/ NIHMS168786; NLM/ PMC2837538
  •  go-up   go-down


27. Li JN, Lv FZ, Xiao JL: [Effects of emodin on proliferation cycle and apoptotic gene of human lung adenocarcinoma cell line Anip 973]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Nov;26(11):1015-7, 1020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of emodin on proliferation cycle and apoptotic gene of human lung adenocarcinoma cell line Anip 973].
  • OBJECTIVE: To study the suppressive role of emodin on the growth and its effect on the proliferation cycle and apoptotic gene of human lung adenocarcinoma cell line Anip 973.

  • Hazardous Substances Data Bank. EMODIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17186734.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.22.- / Caspase 3; KA46RNI6HN / Emodin
  •  go-up   go-down


28. Molina EJ, Mayer K, Khurana J, Grewal H: Pleomorphic adenoma of the submandibular gland. J Pediatr Surg; 2008 Jun;43(6):1224-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the submandibular gland.
  • Pleomorphic adenomas of the submandibular glands are exceedingly rare tumors in the pediatric practice.
  • Radiologic studies are usually unable to differentiate benign from malignant tumors in most cases.
  • Except for the rare cases of malignant transformation, the prognosis is excellent.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Submandibular Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558215.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Owers C, Stewart Dj, Stone J, Kelty C: Hearing loss as an unusual consequence of metastatic gastric adenocarcinoma. J Surg Case Rep; 2010;2010(8):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing loss as an unusual consequence of metastatic gastric adenocarcinoma.
  • Upper gastrointestinal endoscopy and biopsies revealed a gastro-oesophageal junction adenocarcinoma.
  • Despite the absence of metastatic disease on computed tomography, positron emission tomography demonstrated multiple vertebral and sternal deposits.
  • Magnetic resonance imaging identified bilateral 2cm lesions at the internal auditory meatus, consistent with a diagnosis of bilateral acoustic neuromas.
  • Unexpectedly, this revealed bilateral adenocarcinoma metastases infiltrating the internal auditory meatus affecting the acoustic nerves.
  • The authors believe this a very rare presentation of metastatic gastric disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © JSCR.
  • (PMID = 24946349.001).
  • [ISSN] 2042-8812
  • [Journal-full-title] Journal of surgical case reports
  • [ISO-abbreviation] J Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3649159
  •  go-up   go-down


30. Horváth OP, Kalmár K: Early-stage adenocarcinoma in Barrett's esophagus: aspects of surgical therapies. Dig Dis; 2009;27(1):45-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage adenocarcinoma in Barrett's esophagus: aspects of surgical therapies.
  • Adenocarcinomas in Barrett's esophagus are increasingly diagnosed at early stages thanks to effective surveillance programs.
  • Subtotal esophagectomy with extended lymphadenectomy is considered the best curative treatment for patients with early adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagoscopy
  • [MeSH-minor] Ablation Techniques. Humans. Lymph Node Excision. Lymphatic Metastasis. Minimally Invasive Surgical Procedures. Neoplasm Recurrence, Local. Neoplasm Staging. Respiratory Mucosa / pathology. Respiratory Mucosa / surgery

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439960.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 55
  •  go-up   go-down


31. Adlam DJ, Dabbous MK, Woolley DE: Electrochemical monitoring of rat mammary adenocarcinoma cells: an in vitro assay for anticancer drug selection. Assay Drug Dev Technol; 2008 Dec;6(6):795-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemical monitoring of rat mammary adenocarcinoma cells: an in vitro assay for anticancer drug selection.
  • We report the application of an electrochemical biosensor (Oncoprobe; Marks & Clerk, Manchester, UK) to determine whether changes in the open circuit potential (OCP) of rat mammary adenocarcinoma cells (MTLn3) treated in vitro with four cytotoxic anticancer drugs could predict their effects in vivo.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / therapeutic use. Electrochemical Techniques / instrumentation. Electrochemical Techniques / methods. Mammary Neoplasms, Animal / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231941.001).
  • [ISSN] 1540-658X
  • [Journal-full-title] Assay and drug development technologies
  • [ISO-abbreviation] Assay Drug Dev Technol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oxazines; 0 / Xanthenes; 1FN9YD6968 / resazurin; 9007-49-2 / DNA; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


32. Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsimäki P, Fey V, Kytömäki L, Saukko P, Carpén O, Soini JT, Grénman S, Auranen A: Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. Int J Gynecol Cancer; 2009 Oct;19(7):1226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors.
  • INTRODUCTION: Tumor grade is one of the most important prognostic factors in endometrioid endometrial adenocarcinoma.
  • To examine the biological differences between low-grade and high-grade endometrioid endometrial adenocarcinomas, we compared gene expression in these 2 types of tumors.
  • METHODS: Six well-differentiated adenocarcinomas and 7 poorly differentiated adenocarcinomas were studied with 2 different microarray platforms, Affymetrix and Illumina.
  • The expression of the most differentially expressed gene on both platforms was further studied in 34 endometrial adenocarcinoma samples (10 well differentiated, 9 moderately differentiated, and 15 poorly differentiated) using real-time reverse transcription-polymerase chain reaction.
  • In the poorly differentiated adenocarcinomas, APOE was overexpressed 13.1-fold (P = 0.001) and 9.7-fold (P = 0.007) when compared with well- and moderately differentiated tumors, respectively.
  • There was no difference in APOE expression between well- and moderately differentiated adenocarcinomas.
  • CONCLUSIONS: Increased expression of APOE might represent a late event in the progression of well-differentiated endometrioid endometrial adenocarcinoma to a poorly differentiated endometrioid endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Apolipoproteins E / genetics. Cell Differentiation / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Disease Progression. Female. Gene Expression Profiling / instrumentation. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / instrumentation. Oligonucleotide Array Sequence Analysis / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823059.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E
  •  go-up   go-down


33. Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA: Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol; 2009 Dec;182(6):2689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological behavior of single focus prostate adenocarcinoma.
  • PURPOSE: With the increasing use of focal therapy for prostate adenocarcinoma a pathological basis for its appropriate application must be established.
  • MATERIALS AND METHODS: We queried the Center for Prostate Disease Research database for all patients who underwent radical prostatectomy at Walter Reed Army Medical Center from 1993 through 2008.
  • Patients with single focus prostate adenocarcinoma were compared with those who had multifocal disease.
  • Multifocal disease was present in 1,056 patients (99.1%) and 103 (8.9%) had single focus disease.
  • There were statistically higher rates of positive surgical margins (41.0% vs 29.9%, p = 0.0012), Gleason score 8-10 disease (18.7% vs 10.1%, p = 0.0362) and biochemical recurrence (38.5% vs 24.2%, p = 0.0021) in the single focus and multifocal groups, respectively.
  • CONCLUSIONS: Single focus prostate cancer appears to have more aggressive behavior than multifocal disease.
  • These findings support an aggressive, disciplined pretreatment evaluation to define disease site, extent and grade before focal therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836800.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Nassif AE, Tâmbara Filho R, Paula RX, Taguchi WS, Pozzobon HJ: [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir; 2009 Aug;36(4):327-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment].
  • [Transliterated title] Perfil epidemiológico e fatores prognósticos no tratamento cirúrgico do adenocarcinoma de próstata clinicamente localizado.
  • RESULTS: Of 500 patients with clinical localized disease with a median follow up of 36,7 + or - 18,8 months.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076923.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


35. Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC: Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res; 2008 Jan 1;14(1):162-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
  • PURPOSE: Whole-brain radiation therapy (WBRT) has been applied to inoperable brain metastases in lung adenocarcinoma.
  • To elucidate the role of EGFR mutations in radiation treatment, we evaluated the clinical response to WBRT and survival of lung adenocarcinoma patients with brain metastases.
  • EXPERIMENTAL DESIGN: This was a retrospective analysis of 63 patients with brain metastases from lung adenocarcinoma who were treated with WBRT.
  • CONCLUSIONS: Both the EGFR mutations and the administration of EGFR TKI during WBRT were independent predictors of response to WBRT in brain metastases of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brain Neoplasms / radiotherapy. Lung Neoplasms / radiotherapy. Radiation Tolerance / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172267.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


36. Berges O, Belkacemi Y, Giraud P: [Normal tissue tolerance to external beam radiation therapy: thyroid]. Cancer Radiother; 2010 Jul;14(4-5):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dose de tolérance des tissus sains: la thyroïde.
  • The morphological changes consist of benign lesions, primarily adenomas, and malignant lesions, the most feared and which incidence is 0.35%.

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20594893.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


37. Suzuki M, Iizasa T, Nakajima T, Kubo R, Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T: Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis. Ann Surg Oncol; 2007 Sep;14(9):2636-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
  • BACKGROUND: Interleukin-12 receptor beta2 (IL-12Rbeta2) knock-out mice develop lung adenocarcinoma, and epigenetic silencing by CpG methylation leads to loss of this gene in B-cell malignancies.
  • IL-12Rbeta2 methylation correlated with poorer prognosis in lung adenocarcinomas (hazard ratio = 2.33, P = 0.0059).
  • Aberrant methylation of this gene seems to be a useful predictor of long-term outcome for adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Interleukin-12 / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602269.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


38. Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Höög A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol; 2006;27(4):211-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
  • OBJECTIVE: To identify molecular markers useful for the diagnostic discrimination of benign and malignant follicular thyroid tumors.
  • The study included tumor tissue specimens from 10 patients with benign follicular adenomas and from 10 with malignant tumors.
  • The malignant tumors mainly consisted of clinically relevant minimally invasive follicular carcinomas.
  • FHL1 was significantly underexpressed in carcinomas compared to adenomas in the independent panel of tumors.
  • The results indicate that a small number of genes can be useful to distinguish follicular adenomas from follicular carcinomas.
  • [MeSH-major] Adenoma / genetics. Genetic Markers. Thyroid Diseases / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. DNA Primers. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16675914.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers
  •  go-up   go-down


39. Wang P, Zhang Q, Yang JF, Cheng ZN, Zhang K, Yu DH: [Epstein-Barr virus infection and p16(INK4a) overexpression in gastric adenocarcinoma]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug;22(4):244-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus infection and p16(INK4a) overexpression in gastric adenocarcinoma].
  • OBJECTIVE: To study Epstein-Barr virus infection and p16 protein abnormal expresson in carcinogenesis and progression of gastric adenocarcinomas (GAC).
  • RESULTS: EBV LMP-1 and p16 protein were detected in 30.9% (30/97) and in 63.91% (62/97) cases of gastric adenocarcinomas respectively.
  • 2. P16 gene abnormality is frequently involved in GAC and might be one of the important prognostic factors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / virology. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Epstein-Barr Virus Infections / genetics. Gene Expression Regulation, Neoplastic. Stomach Neoplasms / genetics. Stomach Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Viral Matrix Proteins / genetics. Viral Matrix Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105332.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


40. Matsushima H, Oda T, Hasejima N, Kou E, Kadoyama C, Takezawa S: [Pulmonary adenocarcinoma with multiloculated cystic change]. Nihon Kokyuki Gakkai Zasshi; 2007 Jul;45(7):556-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary adenocarcinoma with multiloculated cystic change].
  • A 63-year-old man was admitted to our hospital for evaluation of an abnormal chest X-ray film finding.
  • The pathological examination of trans-bronchial lung biopsy specimen revealed adenocarcinoma.
  • The histological examination showed that papillary adenocarcinoma proliferated along the alveolar walls and that the walls of the multiloculated cystic lesions were composed of cancer cells.
  • We speculated that adenocarcinoma cells extended along the alveolar walls and destroyed the alveoli without disrupting the overall lung architecture, resulting in enlarged multiloculated cystic lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Cysts / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682467.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • We report three cases of unusual tubal-type endocervical glandular proliferations simulating minimal deviation adenocarcinoma in women with a history of in utero diethylstilbestrol (DES) exposure.
  • The proliferations lacked features of mucinous and tubo-endometrioid types of minimal deviation adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Cervix Uteri / pathology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Mitosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


42. Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP, Hanash SM: Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res; 2005 Mar;3(3):119-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation.
  • To uncover gene expression changes related to tumor formation, gene expression profiles of human lung adenocarcinoma (A549) cells grown as lung tumors in immune-compromised mice were compared with profiles of the same cells grown in vitro.
  • Genes that were both selectively induced in vivo and overexpressed in human lung adenocarcinoma tumors included CSPG2, which has not been associated previously with tumor formation.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Animals. Anoxia. Cell Line, Tumor. Female. Humans. Lung / metabolism. Lung / pathology. Mice. Mice, Nude. Models, Biological. Mutation. Neoplasm Transplantation. Proteins / metabolism. RNA / metabolism. RNA Interference. Signal Transduction. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798092.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09676
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 63231-63-0 / RNA
  •  go-up   go-down


43. Tursi M, Costa T, Valenza F, Aresu L: Adenocarcinoma of the disseminated prostate in a cat. J Feline Med Surg; 2008 Dec;10(6):600-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the disseminated prostate in a cat.
  • An adenocarcinoma of the disseminated prostate gland with pulmonary, myocardial and renal metastases is described in a 12-year-old, neutered male European cat.
  • Considering the anatomic, microscopic and immunohistochemical findings, the tumour was diagnosed as an adenocarcinoma of the disseminated prostate gland.
  • To our knowledge this is the first report of adenocarcinoma of the disseminated prostate gland in a cat.
  • [MeSH-major] Adenocarcinoma / veterinary. Cat Diseases / pathology. Prostatic Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Fatal Outcome. Immunohistochemistry / veterinary. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621560.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Zhang L, Higashi K, Ishigaki Y, Ueda Y, Sakuma T, Takegami T, Oguchi M, Xu K, Ohta Y, Nishida H, Tonami H: Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma. Ann Nucl Med; 2010 Aug;24(7):533-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
  • OBJECTIVE: To assess whether the combined evaluation of vascular endothelial growth factor D (VEGF-D) expression and fluorodeoxyglucose (FDG) uptake correlates with lymph node metastasis and post-operative recurrence in patients with lung adenocarcinoma.
  • METHODS: Forty-six patients with lung adenocarcinomas, who had undergone both preoperative FDG PET imaging and thoracotomy, were enrolled in this study.
  • The 5-year disease-free survival rates were 66.7% in group I, 83.9% in group II, 8.3% in group III, and 64.0% in group IV (p < 0.0001).
  • CONCLUSION: A combination of low VEGF-D expression and high FDG uptake may be a biological indicator of lymph node metastasis and post-operative recurrence in patients with lung adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Biological Transport. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Postoperative Period. Prognosis. Recurrence. Retrospective Studies. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20607627.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor D; 0Z5B2CJX4D / Fluorodeoxyglucose F18; Adenocarcinoma of lung
  •  go-up   go-down


45. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z, Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2835-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results.
  • EXPERIMENTAL DESIGN: Total RNA was extracted, amplified, and biotinylated from frozen colonic biopsies of patients with colorectal cancer (n=22), adenoma (n=20), hyperplastic polyp (n=11), inflammatory bowel disease (n=21), and healthy normal controls (n=11), as well as peripheral blood samples of 19 colorectal cancer and 11 healthy patients.
  • RESULTS: Adenoma samples could be distinguished from hyperplastic polyps by the expression levels of nine genes including ATP-binding cassette family A, member 8, insulin-like growth factor 1 and glucagon (sensitivity, 100%; specificity, 90.91%).
  • Between low-grade and high-grade dysplastic adenomas, 65 classifier probesets such as aquaporin 1, CXCL10, and APOD (90.91/100) were identified; between colorectal cancer and adenoma, 61 classifier probesets including axin 2, von Willebrand factor, tensin 1, and gremlin 1 (90.91/100) were identified.
  • [MeSH-minor] Adenoma / blood. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Case-Control Studies. Chi-Square Distribution. Colonic Polyps / blood. Colonic Polyps / genetics. Colonic Polyps / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Inflammatory Bowel Diseases / blood. Inflammatory Bowel Diseases / pathology. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


46. Mitterberger M, Horninger W, Aigner F, Pinggera GM, Rehder P, Steiner E, Wiunig C, Reissigl A, Frauscher F: Contrast-enhanced colour Doppler-targeted vs a 10-core systematic repeat biopsy strategy in patients with previous high-grade prostatic intraepithelial neoplasia. BJU Int; 2010 Jun;105(12):1660-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced colour Doppler-targeted vs a 10-core systematic repeat biopsy strategy in patients with previous high-grade prostatic intraepithelial neoplasia.
  • OBJECTIVE: To compare the results of contrast-enhanced colour Doppler (CECD)-targeted prostate biopsy with a systematic 10-core grey-scale biopsy scheme in patients initially diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN), as although HGPIN is thought to be a precursor to invasive adenocarcinoma, its diagnosis is no longer considered an indication for repeat prostate biopsy and patients should be followed by prostate-specific antigen levels and a digital rectal examination.
  • [MeSH-major] Biopsy, Needle / methods. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863528.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


47. Wakamatsu N, Collins JB, Parker JS, Tessema M, Clayton NP, Ton TV, Hong HH, Belinsky S, Devereux TR, Sills RC, Lahousse SA: Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors. Toxicol Pathol; 2008 Jul;36(5):743-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • National Toxicology Program (NTP) inhalation studies demonstrated that cumene significantly increased the incidence of alveolar/bronchiolar adenomas and carcinomas in B6C3F1 mice.
  • Gene expression analysis also suggested that cumene-induced carcinomas with K-ras mutations have greater malignant potential than those without mutations.
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / chemically induced. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Animals. Female. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Male. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Isopropylbenzene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648096.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES008801; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzene Derivatives; 8Q54S3XE7K / cumene; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


48. Olmo N, Turnay J, Pérez-Ramos P, Lecona E, Barrasa JI, López de Silanes I, Lizarbe MA: In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells. Toxicol In Vitro; 2007 Mar;21(2):262-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells.
  • The effect of butyrate has been analyzed on human colon adenocarcinoma cell lines with different properties regarding tumorigenicity, differentiation and resistance to apoptosis induced by this agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Butyrates / pharmacology. Colonic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084582.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Butyrates; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


49. Yagi K, Aruga Y, Nakamura A, Sekine A, Umezu H: The study of dynamic chemical magnifying endoscopy in gastric neoplasia. Gastrointest Endosc; 2005 Dec;62(6):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The study of dynamic chemical magnifying endoscopy in gastric neoplasia.
  • BACKGROUND: We assessed the usefulness of acetic acid-enhanced magnifying endoscopy in the diagnosis of gastric neoplasia.
  • METHODS: Forty-five patients (27 men, 18 women; median age 61.6 years) with gastric carcinoma or adenoma were enrolled in a prospective trial of enhanced magnifying endoscopy after instillation of 1.5% acetic acid.
  • Acetic acid-enhanced magnified views of carcinoma or adenoma and the surrounding non-neoplastic mucosa were observed, and the duration of whitening time of each lesion was recorded.
  • The histopathologic diagnostic criteria were based on the Vienna classification of GI epithelial neoplasia.
  • The mean duration of whitening differed with each histologic type: low-grade adenoma, 94 seconds; high-grade adenoma, 24.3 seconds; noninvasive carcinoma, 20.1 seconds; invasive intramucosal carcinoma, 3.5 seconds; and submucosal carcinoma or beyond, 2.5 seconds.
  • CONCLUSIONS: Acetic acid-enhanced magnifying endoscopy was useful for the diagnosis of gastric adenocarcinoma.
  • The duration of whitening differed among grades of neoplasia, and it was possible to observe changes in the whitening with time.
  • [MeSH-major] Acetic Acid. Gastric Mucosa / pathology. Gastroscopy. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Female. Humans. Indicators and Reagents. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301045.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


50. Chuang LC, Chen HC, You SL, Lin CY, Pan MH, Chou YC, Hsieh CY, Chen CJ: Association between human papillomavirus and adenocarcinoma of rectum and recto-sigmoid junction: a cohort study of 10,612 women in Taiwan. Cancer Causes Control; 2010 Dec;21(12):2123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between human papillomavirus and adenocarcinoma of rectum and recto-sigmoid junction: a cohort study of 10,612 women in Taiwan.
  • This study aimed at assessing the association between the type-specific human papillomavirus (HPV) infection and the risk of adenocarcinoma of the rectum and recto-sigmoid junction.
  • Newly developed adenocarcinomas of rectum and recto-sigmoid junction were ascertained through computerized linkage with national cancer registry profiles.
  • An increased risk of adenocarcinomas of the rectum and recto-sigmoid junction was observed with HPV infection, showing a hazard ratio [HR] (95% confidence interval [CI]) of 1.99 (0.98-4.04) after adjustment for age and body mass index.
  • Women with cervical infection of HPV types other than 6 and 11 at study entry may have an increased risk of adenocarcinomas of the rectum and recto-sigmoid junction, which deserves further validation by large-scale studies.
  • [MeSH-major] Adenocarcinoma / epidemiology. Papillomavirus Infections / epidemiology. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721617.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


51. de Meis E, Monteiro RQ, Levy RA: Lung adenocarcinoma and antiphospholipid antibodies. Autoimmun Rev; 2009 May;8(6):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma and antiphospholipid antibodies.
  • Thrombosis is a frequent finding in cancer patients, being referred to as a poor prognostic factor.
  • A prospective analysis has been performed in a group of lung adenocarcinoma patients in respect to the presence of aPL and thrombotic manifestations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Antibodies, Antiphospholipid / blood. Lung Neoplasms / diagnosis. Lung Neoplasms / immunology
  • [MeSH-minor] Autoantibodies / blood. Blood Coagulation. Humans. Immunoglobulin M / blood. Immunoglobulin M / immunology. Lupus Coagulation Inhibitor / immunology. Neoplasm Staging. Prognosis. Prospective Studies. Risk Factors. Survival Analysis. Thrombosis. beta 2-Glycoprotein I / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185619.001).
  • [ISSN] 1873-0183
  • [Journal-full-title] Autoimmunity reviews
  • [ISO-abbreviation] Autoimmun Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


52. Wei S, Liang Z, Gao J, Wu S, Zhu H, Liu H, Liu T: Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroenterol Hepatol; 2005 Jan;20(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing.
  • BACKGROUND AND AIM: To our knowledge there are few reports on the K-ras mutation pattern of pancreatic adenocarcinoma from Chinese mainland patients.
  • We examined surgically resected formalin-fixed, paraffin-embedded primary pancreatic adenocarcinoma tissue blocks for the presence of activating point mutations at codon 12 and 13 of the K-ras gene.
  • Twenty-five (83%) of the 30 pancreatic adenocarcinomas examined harbored K-ras mutation.
  • Among the 25 pancreatic adenocarcinomas, 24 showed K-ras mutation at codon 12 (11 with GGT-GTT, seven with GGT-GAT, four with GGT-CGT, and two with GGT-TGT), and only one showed a GGC-TGC mutation at codon 13.
  • CONCLUSIONS: The mutation profiles of K-ras at codon 12 in our pancreatic adenocarcinoma samples were significantly different from those of European and Japanese samples.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras / genetics. Mutation. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610449.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


53. Liu MS, Yang PY, Yeh TS: Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma. Pancreas; 2007 Apr;34(3):340-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma.
  • OBJECTIVES: Hedgehog (Hh) signaling is an important mediator of tumorigenesis of pancreatic ductal adenocarcinoma (PA).
  • METHODS: Patients with solid and pseudopapillary tumor (SPT; n = 12), mucinous cystic neoplasm (MCN; n = 18), intraductal papillary mucinous neoplasm (IPMN; n = 18), and PA (n = 20) were studied.
  • Mucinous cystic neoplasm and PA exhibit an autocrine regulation of sHh, whereas SPT and IPMN do not.
  • [MeSH-major] Adenocarcinoma / physiopathology. Carcinoma, Ductal / physiopathology. Hedgehog Proteins / physiology. Pancreatic Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414057.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / patched receptors
  •  go-up   go-down


54. Gatenby PA, Ramus JR, Caygill CP, Charlett A, Winslet MC, Watson A: Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus; 2009;22(2):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus.
  • Columnar metaplasia is the precursor lesion for esophageal adenocarcinoma, resulting from prolonged gastroesophageal reflux.
  • This study compares the rate of development of dysplasia and adenocarcinoma in patients with columnar metaplasia of the esophagus between patients treated pharmacologically and those treated with antireflux surgery.
  • No patient in the surgical group developed high-grade dysplasia (HGD) or adenocarcinoma.
  • Twenty patients treated medically developed adenocarcinoma and 10 developed HGD.
  • Hazards ratio comparing pharmacological to surgical therapy for development of all grades of dysplasia and adenocarcinoma 1.77 (P = 0.272).
  • Log rank test comparing antireflux surgery to pharmacological therapy for development of HGD or adenocarcinoma P = 0.1287 and for adenocarcinoma P = 0.2125.
  • Although there was a trend towards greater efficacy of antireflux surgery over pharmacological therapy in reducing the development of dysplasia and adenocarcinoma, this did not reach statistical significance.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018855.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  •  go-up   go-down


55. Saad RS, Lindner JL, Liu Y, Silverman JF: Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol; 2009 Jan;131(1):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma.
  • We studied tumor lymphatic vascular density (LVD) as a predictive marker for the risk of lymph node (LN) metastasis and its relationship to other prognostic parameters and survival in 75 patients with esophageal adenocarcinoma.
  • D2-40 LVD demonstrated a significant correlation with LN metastases, lymphovascular invasion, and tumor stage (r = 0.45, r = 0.47, and r = 0.37, respectively) and with shorter disease-free survival.
  • Our study showed that angiogenesis and lymphangiogenesis have important roles in the progression of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Lymphatic Vessels / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095571.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / monoclonal antibody D2-40
  •  go-up   go-down


56. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai; 2008 Aug;91(8):1161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
  • OBJECTIVE: To investigate PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression in endometrial hyperplasia and adenocarcinoma as analyzed by immunohistochemistry.
  • MATERIAL AND METHOD: PTEN protein expression was evaluated by immunohistrochemical study of 70 paraffin-embedded curettage endometrial tissue samples (10 normal endometrium, 55 endometrial hyperplasia, and 15 endometrial adenocarcinomas) selected from surgical pathology files of the Division of Gynecologic Pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, from 2001 to 2004.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / diagnosis. Endometrium / cytology. PTEN Phosphohydrolase / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788685.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


57. De Gabory L, Conso F, Barry B, Stoll D: [Carcinogenesis of the ethmoidal adenocarcinoma due to wood dust]. Rev Laryngol Otol Rhinol (Bord); 2009;130(2):93-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinogenesis of the ethmoidal adenocarcinoma due to wood dust].
  • [Transliterated title] La carcinogenèse de l'adénocarcinome de l'ethmoïde aux poussières de bois.
  • OBJECTIVES: To recognize the mechanisms and the different oncogenic pathways of ethmoid adenocarcinoma (EADC) in woodworkers.
  • Certain biomolecular and genetic factors are shared with the adenocarcinoma of the colon but they are not activated with the same importance and in the same context suggesting two distinct mechanisms of evolution.
  • [MeSH-major] Adenocarcinoma / etiology. Ethmoid Sinus. Occupational Diseases / etiology. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813471.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dust
  • [Number-of-references] 110
  •  go-up   go-down


58. Srikureja W, Chang KJ: Endoscopic palliation of pancreatic adenocarcinoma. Curr Opin Gastroenterol; 2005 Sep;21(5):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic palliation of pancreatic adenocarcinoma.
  • PURPOSE OF REVIEW: Endoscopic therapies have become an indispensable modality in the treatment and palliation of complications from pancreatic adenocarcinoma.
  • This review focuses on treatment of biliary obstruction, malignant gastric outlet obstruction, and intractable abdominal pain resulting from unresectable pancreatic adenocarcinoma.
  • SUMMARY: The frontier of endoscopic palliative therapies for pancreatic adenocarcinoma is expanding.
  • [MeSH-major] Adenocarcinoma / surgery. Endoscopy, Gastrointestinal. Palliative Care / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093777.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


59. Kawaguchi T, Ochiai T, Ikoma H, Inoue K, Morimura R, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Okamoto K, Fujiwara H, Kokuba Y, Sonoyama T, Otsuji E: Prognostic impact of histological blood vessel invasion in patients with ampullary adenocarcinoma. Hepatogastroenterology; 2010 Nov-Dec;57(104):1347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of histological blood vessel invasion in patients with ampullary adenocarcinoma.
  • BACKGROUNDS/AIMS: Ampullary adenocarcinoma (AmpCA) has a greater overall survival (OS) rate than other periampullary cancers such as pancreatic cancer or bile duct cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21443083.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


60. Sangoi AR, McKenney JK: A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol; 2010 Mar;34(3):423-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have encountered an increasing number of image-guided adrenal mass biopsies in which the differential diagnosis is adrenal cortical lesion versus pheochromocytoma.
  • In this study, a detailed immunoprofile of 63 adrenal cortical lesions (3 adrenal rests, 6 adrenal cortical hyperplasias, 43 adrenal cortical adenomas, 4 adrenal cortical neoplasms of uncertain malignant potential, and 7 adrenal cortical carcinomas) was compared with 35 pheochromocytomas using traditional (calretinin, chromogranin, inhibin, melanA, and synaptophysin) and novel [steroidogenic factor-1 (SF-1), microtubule-associated protein 2, and mammalian achaete-scute homolog-1] antibodies, using tissue microarray technology to simulate small image-guided biopsies.
  • [MeSH-major] Adenoma / chemistry. Adrenal Cortex Neoplasms / chemistry. Adrenal Gland Neoplasms / chemistry. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Immunohistochemistry. Pheochromocytoma / chemistry. Tissue Array Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Artifacts. Biopsy. Calbindin 2. Child. Child, Preschool. Chromogranins / analysis. Diagnosis, Differential. Female. Humans. Infant. Inhibins / analysis. Male. Middle Aged. Predictive Value of Tests. S100 Calcium Binding Protein G / analysis. Sensitivity and Specificity. Steroidogenic Factor 1 / analysis. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154585.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Chromogranins; 0 / NR5A1 protein, human; 0 / S100 Calcium Binding Protein G; 0 / Steroidogenic Factor 1; 57285-09-3 / Inhibins
  •  go-up   go-down


61. Peters CJ, Fitzgerald RC: Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther; 2007 Jun 01;25(11):1253-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma.
  • BACKGROUND: Oesophageal adenocarcinoma is an increasingly common cancer with a poor prognosis.
  • It develops in a stepwise progression from Barrett's metaplasia to dysplasia, and then adenocarcinoma followed by metastasis.
  • AIM: To outline the key molecular changes in oesophageal adenocarcinoma and to summarize the chemopreventative and therapeutic strategies proposed.
  • Search terms included: Barrett's (o)esophagus, intestinal metaplasia, (o)esophageal adenocarcinoma, molecular changes, genetic changes, pathogenesis, chemoprevention, therapeutic strategies and treatment.
  • RESULTS: A large number of molecular changes have been identified in the progression from Barrett's oesophagus to oesophageal adenocarcinoma although there does not appear to be an obligate order of events.
  • In established adenocarcinoma, targeted treatments under evaluation include receptor tyrosine kinase inhibitors of EGFR and cyclin-dependent kinase inhibitors, which may benefit a subgroup of patients.
  • CONCLUSIONS: Advances in molecular methodology have led to a greater understanding of the oesophageal adenocarcinoma pathways, which provides opportunities for chemoprevention and therapeutic strategies with a mechanistic basis.
  • [MeSH-major] Adenocarcinoma / prevention & control. Angiogenesis Inhibitors / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antioxidants / therapeutic use. Esophageal Neoplasms / prevention & control
  • [MeSH-minor] Cell Proliferation. Chemoprevention / methods. Disease Progression. Duodenogastric Reflux / prevention & control. Genes, erbB. Humans

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509094.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Inflammatory Agents; 0 / Antioxidants
  • [Number-of-references] 149
  •  go-up   go-down


62. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ: Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol; 2010 Jan;21(1):78-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.
  • As such, proteinase-activated receptor (PAR)-1, endostatin (ES) and interleukin-8 (IL-8) mediate the regulation of early-onset angiogenesis and in turn impact the process of tumor-growth and disease progression.
  • CONCLUSIONS: Polymorphisms in PAR-1, ES, and IL-8 may serve as independent molecular prognostic markers in patients with localized gastric adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2004 Aug;31(4):566-73 [15297947.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3369-76 [12626597.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11361-8 [9111044.001]
  • [Cites] Nat Med. 1998 Aug;4(8):909-14 [9701242.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1775-7 [9848370.001]
  • [Cites] Pediatr Res. 2004 Dec;56(6):953-9 [15470196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):216-20 [15615851.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):600-5 [15701846.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1833-40 [12406873.001]
  • [Cites] Cytogenet Cell Genet. 2001;94(3-4):147-54 [11856872.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1503-13 [12707033.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 19;95(22):1660-73 [14625257.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):946-56 [15199114.001]
  • [Cites] Nat Med. 2005 Sep;11(9):925-7 [16145572.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6431-41 [16166417.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2487-93 [16284368.001]
  • [Cites] Pharmacogenomics. 2006 Jan;7(1):67-88 [16354126.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):855-60 [16418262.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):62-6 [18172253.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1227-33 [17962514.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):847-54 [18507028.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1734-41 [18550579.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7554-63 [19010874.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7884-95 [19047118.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):647-53 [10574250.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):585-92 [10669659.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6868-75 [10702246.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1793-6 [10766159.001]
  • [Cites] Thorax. 2000 Dec;55(12):1023-7 [11083887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6470-5 [11353854.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7375-8 [11606364.001]
  • [Cites] Nature. 1991 Oct 17;353(6345):674-7 [1717851.001]
  • (PMID = 19622587.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5 P30CA14089-27I
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endostatins; 0 / Interleukin-8; 0 / Receptor, PAR-1
  • [Other-IDs] NLM/ PMC2795613
  •  go-up   go-down


63. Czaykowski P, Hui D: Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol); 2007 Mar;19(2):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.
  • AIMS: Small bowel adenocarcinoma (SBA) is a rare, frequently lethal, malignancy.
  • Thirty-seven patients initially or eventually had advanced disease: 16 received 22 palliative intent fluoropyrimidine-based regimens.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355111.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


64. Theodoropoulos G, Panoussopoulos D, Papaconstantinou I, Gazouli M, Perdiki M, Bramis J, Lazaris ACh: Assessment of JC polyoma virus in colon neoplasms. Dis Colon Rectum; 2005 Jan;48(1):86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A nested polymerase chain reaction assay was used to detect JC virus in 80 cancerous, 25 adenomatous specimens of large bowel, and 20 colonoscopic biopsy samples from normal patients without colorectal neoplasia.
  • RESULTS: JC polyoma virus nucleotide sequence was detected in 61 percent of colon adenocarcinomas and in 60 percent of adenomas, at a viral load of 9 x 10(3) to 20 x 10(3) copies/microg DNA.
  • Adjacent normal mucosa in 35 positive colon adenocarcinoma specimens, and normal mucosa from six patients of the control group, had low viral loads (50-450 copies/microg DNA).
  • JC virus detection in adenomas at comparable viral loads to malignant tumors suggests its implication at early steps of colonic carcinogenesis.
  • [MeSH-major] Adenocarcinoma / virology. Adenoma / virology. Colonic Neoplasms / virology. JC Virus / pathogenicity. Tumor Virus Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690663.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


65. Masi G, Lavezzo E, Iacobone M, Favia G, Palù G, Barzon L: Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. J Endocrinol Invest; 2009 Jul;32(7):597-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At variance, activating mutations of another oncogene, CTNNB1, which encodes beta-catenin, have been shown to be common events in both benign and malignant adrenocortical tumors.
  • MATERIALS AND METHODS: Tissue samples from 15 adrenocortical carcinomas and 41 adrenocortical adenomas were investigated for the presence of BRAF and CTNNB1 activating mutations by PCR amplification and direct sequencing.
  • RESULTS: An advanced invasive non-functioning adrenocortical carcinoma carried a somatic heterozygous BRAF V600E mutation, while 4 functioning and 4 non-functioning adenomas and 3 functioning carcinomas carried different CTNNB1 activating mutations.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):565-72 [19190079.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Endocr Rev. 2007 Dec;28(7):742-62 [17940185.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Eur J Endocrinol. 2002 Jan;146(1):61-6 [11751069.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):855-60 [15613458.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2551-9 [18451216.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2000;108(8):513-4 [11149627.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Eur J Endocrinol. 2008 Jul;159(1):77-80 [18426810.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):31-9 [17208430.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1060-5 [9569040.001]
  • [Cites] J Endocrinol Invest. 2007 Jan;30(1):RC1-3 [17318013.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Feb;68(2):264-70 [17854394.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40 [18647815.001]
  • [Cites] Eur J Endocrinol. 2003 Oct;149(4):273-85 [14514341.001]
  • [Cites] Oncogene. 2008 Feb 7;27(7):877-95 [17724477.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):496-505 [16880792.001]
  • [Cites] Development. 2008 Aug;135(15):2593-602 [18599507.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] J Urol. 1993 Jun;149(6):1389-94 [8501773.001]
  • (PMID = 19498322.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


66. Takakura S, Saito M, Ueda K, Motegi M, Takao M, Yamada K, Okamoto A, Niimi S, Sasaki H, Tanaka T, Ochiai K: Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma. Int Surg; 2007 Jul-Aug;92(4):202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
  • Patients with ovarian clear cell adenocarcinoma (OCCA) show a poor response to conventional platinum-based chemotherapy.
  • Two complete responses (CRs) were obtained in the three patients with measurable disease, and response duration was 7 and 15 months, respectively.
  • One patient had stable disease (SD), and the time to progression was 5 months.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050828.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


67. Veshapidze N, Alibegashvili M, Chigogidze T, Gabunia N, Kotrikadze N: Dynamics of the protein spectrum changes in blood erythrocytes of male patients with prostate adenocarcinoma after plastic orchiectomy. Georgian Med News; 2007 Feb;(143):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the protein spectrum changes in blood erythrocytes of male patients with prostate adenocarcinoma after plastic orchiectomy.
  • We have studied erythrocytes electrophoresis profiles in patients with prostate adenocarcinoma before and after plastic orchectomy and in healthy men to detect changes in the protein spectrum of erythrocytes.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / surgery. Erythrocytes / metabolism. Orchiectomy / methods. Prostatic Neoplasms / blood. Prostatic Neoplasms / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404435.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


68. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab; 2005 Mar;90(3):1819-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to identify predictor sets of genes whose over- or underexpression in human sporadic adrenocortical tumors would help to identify malignant vs. benign tumors and to predict postsurgical metastatic recurrence.
  • For this, we analyzed the expression of 230 candidate genes using cDNA microarrays in a series of 57 well-characterized human sporadic adrenocortical tumors (33 adenomas and 24 carcinomas).
  • Taken together, these results show that the parallel analysis of the expression levels of a selected group of genes on microgram quantities of tumor RNA (a quantity that can be obtained from fine needle aspirations) appears as a complementary method to histopathology for the diagnosis and prognosis of evolution of adrenocortical carcinomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Genetic Markers. Humans. Male. Middle Aged. RNA, Messenger / analysis. Steroids / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2005 Mar;90(3):1900-2 [15758065.001]
  • (PMID = 15613424.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / RNA, Messenger; 0 / Steroids
  •  go-up   go-down


69. Sahin A, Kiratli H: Choroidal metastasis as a first sign of recurrence in a patient with gastric adenocarcinoma. Can J Ophthalmol; 2007 Apr;42(2):331-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis as a first sign of recurrence in a patient with gastric adenocarcinoma.
  • CASE REPORT: A 40-year-old man with a history of gastric adenocarcinoma presented with progressive visual loss in his right eye.
  • COMMENTS: This patient represents a rare occurrence of metastatic gastric adenocarcinoma to the choroid and optic nerve, developing as a first sign of systemic recurrence.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392868.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Rosbottom KJ, Michie B, Boyce S: Metastasis of recurrent colonic adenocarcinoma to the mouth. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of recurrent colonic adenocarcinoma to the mouth.
  • Colorectal adenocarcinoma is a common cancer; however, reports of metastases to the oral region are uncommon.
  • Oral metastases often indicate disseminated disease, the prognosis is poor and management is often palliative.
  • We report the case of a 73-year-old man with recurrent metastatic disease who presented 2 years following his initial surgery for a left-sided colonic adenocarcinoma with a painful oral tumour.
  • Biopsy confirmed adenocarcinoma with similar features to the original colonic tumour; the patient went on to have palliation of his symptoms with radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Surg. 1975 Jan;33(1):53-6 [1053651.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Feb;41(1):3-6 [12576032.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1965 Sep;20:350-62 [14342927.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):355-60 [8746264.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):743-52 [18061527.001]
  • [Cites] J Oral Pathol. 1987 Aug;16(7):362-7 [3117991.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • (PMID = 21754956.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028428
  •  go-up   go-down


71. Smith R, Hicks D, Tomljanovich PI, Lele SB, Rajput A, Dunn KB: Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature. Am Surg; 2008 Jan;74(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature.
  • Perianal disease is a common manifestation of Crohn's disease.
  • We present a unique case of a perianal Crohn's disease with adenomatous epithelialization of a fistula tract and an associated mucinous adenocarcinoma.
  • Our case demonstrates that mucinous adenocarcinoma can arise in long standing perianal Crohn's disease and may be associated with adenomatous transformation of the epithelial lining of the fistula tract.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Crohn Disease / pathology. Rectal Fistula / etiology
  • [MeSH-minor] Aged. Chronic Disease. Female. Humans

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274431.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


72. Patel T, Viswanathan S, Jambhekar NA: Metastatic adenocarcinoma presenting as an inguinal hernia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Jul;50(3):541-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma presenting as an inguinal hernia: a case report and review of literature.
  • Histopathological examination of the hernial sac revealed metastatic deposits of a mucin secreting adenocarcinoma which was confirmed by subsequent tumor marker levels.
  • Patient was put on chemotherapy for disseminated adenocarcinoma and is tolerating it well.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Hernia, Inguinal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883127.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 13
  •  go-up   go-down


73. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • The poorly differentiated adenocarcinomas also exhibited coexpression of CK5 and p63.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


74. Dias AR, Pinto RA, Mory E, Silva IC, Siqueira SA, Nahas SC, Cecconello I, Wexner SD: Synchronous collision malignant melanoma and adenocarcinoma of the rectum. Tech Coloproctol; 2010 Jun;14(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous collision malignant melanoma and adenocarcinoma of the rectum.
  • Colorectal collisions are particularly unusual; here, we report the exceedingly rare case of a 61-year-old man with malignant melanoma and adenocarcinoma colliding in the rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1997;194(4):378-9 [9252769.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2515-25 [8952560.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Head Neck. 2004 Jul;26(7):637-41 [15229907.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1280-7 [10524531.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Am J Otolaryngol. 2007 May-Jun;28(3):218-20 [17499145.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1492-8 [15489653.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):285-90 [17630114.001]
  • [Cites] Am J Surg Pathol. 1987;11 Suppl 1:71-86 [3544888.001]
  • [Cites] Arch Pathol Lab Med. 1988 Jan;112(1):91-3 [2447855.001]
  • [Cites] Am J Dermatopathol. 2007 Aug;29(4):395-9 [17667176.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5569-72 [17007003.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23 ):24498-504 [15047714.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):105-8 [9102249.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):131-9 [10697269.001]
  • [Cites] Med Hypotheses. 2002 Apr;58(4):340-6 [12027530.001]
  • [Cites] Pathologica. 1998 Feb;90(1):36-41 [9628978.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Biometrics. 2006 Sep;62(3):721-7 [16984313.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):29-39 [11325514.001]
  • [Cites] Gut. 2006 May;55(5):695-702 [16354798.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • (PMID = 20309715.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


75. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med; 2008 May;37(5):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
  • BACKGROUND: Recent studies have proposed that minichromosome maintenance (Mcm) proteins may be sensitive proliferation markers and may serve as novel biomarkers for prognostication and diagnosis of various pre-malignant and malignant lesions.
  • The aims of this study were to determine the expression of Mcm-2, Ki-67 and geminin in salivary gland (SG) tumours, and to evaluate their usefulness for diagnosis or for prediction of tumour behaviour.
  • There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC).
  • CONCLUSIONS: The findings suggest that Mcm-2 may be a sensitive proliferation marker in SG tumours and may be useful for differential diagnosis between PA and CEPA, and ACC and PLGA.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Geminin. Humans. Immunoenzyme Techniques. Male. Microarray Analysis. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248354.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


76. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W: Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res; 2008 Jul 15;68(14):5524-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
  • We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this pathway that could contribute to lung tumorigenesis.
  • MEK1 mutants have not previously been reported in lung cancer and may provide a target for effective therapy in a small subset of patients with lung adenocarcinoma.


77. Hammoud ZT, Badve S, Saxena R, Kesler KA, Rieger K, Malkas LH, Hickey RJ: A novel biomarker for the detection of esophageal adenocarcinoma. J Thorac Cardiovasc Surg; 2007 Jan;133(1):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel biomarker for the detection of esophageal adenocarcinoma.
  • Our group has recently identified an acidic isoform of proliferating cell nuclear antigen, cancer-specific proliferating cell nuclear antigen, that appears to be present only in malignant tissue.
  • We sought to determine the presence of cancer-specific proliferating cell nuclear antigen in esophageal dysplasias and invasive adenocarcinomas to assess its potential utility in discriminating malignancy.
  • METHODS: With a polyclonal antibody to cancer-specific proliferating cell nuclear antigen, immunohistochemical staining was performed on samples from a total of 30 patients with Barrett esophagus with varying degrees of dysplasia and 18 patients with invasive adenocarcinoma.
  • Of the 18 adenocarcinoma specimens, all stained positively for cancer-specific proliferating cell nuclear antigen.
  • CONCLUSIONS: Cancer-specific proliferating cell nuclear antigen appears to demonstrate high specificity for esophageal adenocarcinoma.
  • Cancer-specific proliferating cell nuclear antigen also holds future promise as a biomarker for esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers / analysis. Esophageal Neoplasms / diagnosis. Proliferating Cell Nuclear Antigen / analysis
  • [MeSH-minor] Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Diagnosis, Differential. Esophagus / metabolism. Humans. Immunohistochemistry. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Protein Isoforms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198786.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proliferating Cell Nuclear Antigen; 0 / Protein Isoforms
  •  go-up   go-down


78. Arathi N, Bage AM: Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):103-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence.
  • Polymorphous low-grade adenocarcinoma (PLGA) is a rare salivary gland malignant tumor of low aggressiveness, commonly occurring in minor salivary glands.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):166-7 [20090256.001]
  • (PMID = 19136798.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


79. Chuang AY, Epstein JI: Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
  • Prostatic xanthoma may mimic high-grade prostatic adenocarcinoma or prostate cancer treated with hormone therapy.
  • Careful attention to morphology with adjunctive use of CD68 and CAM5.2 immunohistochemical stains are helpful in the diagnosis of prostatic xanthoma, especially in difficult cases with an infiltrative pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Biomarkers / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


80. Duenschede F, Bittinger F, Heintz A, Musholt T, Korenkov M, Kann P, Ewald P, Gockel I, Junginger T: Malignant and unclear histological findings in incidentalomas. Eur Surg Res; 2008;40(2):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant and unclear histological findings in incidentalomas.
  • In 45 patients, the adenomas did not meet the defined criteria of malignancy.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Incidental Findings
  • [MeSH-minor] Diagnostic Techniques, Endocrine. Female. Hormones / metabolism. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18032908.001).
  • [ISSN] 1421-9921
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


81. Shameem M, Akhtar J, Baneen U, Bhargava R, Ahmed Z, Sharma P, Khan NA, Hassan MJ: Primary peritoneal adenocarcinoma causes pleural effusion. N Am J Med Sci; 2010 Jun;2(6):281-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal adenocarcinoma causes pleural effusion.
  • CONTEXT: The most common malignancies associated with malignant pleural effusions are carcinomas of the breast, lung, gastrointestinal tract, ovary and lymphomas.
  • Primary peritoneal adenocarcinoma is a very rare cause of malignant pleural effusion.
  • A cytologic examination of pleural fluid revealed adenocarcinoma cells.
  • A histological examination of a peritoneal lesion was suggestive of adenocarcinoma.
  • CONCLUSIONS: The patient was diagnosed with a rare case of primary peritoneal adenocarcinoma with bilateral pleural effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Nov;54(5):656-8 [503399.001]
  • [Cites] Int J Gynecol Pathol. 1994 Apr;13(2):120-6 [8005732.001]
  • [Cites] Gynecol Oncol. 1991 Jun;41(3):259-62 [1714418.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):230-6 [2013445.001]
  • [Cites] Obstet Gynecol. 1990 Jan;75(1):75-8 [2296426.001]
  • [Cites] Gynecol Oncol. 1988 Oct;31(2):315-20 [2458994.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):110-5 [2731107.001]
  • [Cites] J Surg Oncol. 1998 Jul;68(3):173-8 [9701210.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):230-9 [9826465.001]
  • [Cites] Am J Obstet Gynecol. 1959 Jan;77(1):197-200 [13606191.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(6):474-8 [3234425.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1044-9 [7487405.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):171-4 [8276289.001]
  • [Cites] Gynecol Oncol. 1993 Sep;50(3):347-51 [8406199.001]
  • [Cites] Int J Gynecol Pathol. 1995 Oct;14(4):310-8 [8598333.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):160-3 [9234939.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):141-6 [9367697.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):197-9 [16620072.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):762-8 [17383715.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):563-7 [11398893.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):764-70 [14675312.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 1):786-92 [2704507.001]
  • [Cites] Hum Pathol. 1989 May;20(5):426-36 [2707793.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Int J Gynecol Pathol. 1985;4(1):11-23 [3880151.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):905-9 [4016683.001]
  • [Cites] Lancet. 1982 Oct 9;2(8302):795-7 [6126666.001]
  • [Cites] Hum Pathol. 1990 Jan;21(1):99-110 [1688545.001]
  • (PMID = 22574304.001).
  • [ISSN] 1947-2714
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3347636
  • [Keywords] NOTNLM ; Malignant pleural effusion / primary peritoneal adenocarcinoma
  •  go-up   go-down


82. Al-Amri AM: Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report. Oman Med J; 2010 Oct;25(4):303-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report.
  • Planning for treatment of gastric adenocarcinoma in a patient previously treated with partial gastrectomy for primary gastric lymphoma is difficult.
  • Long term survival of advanced gastric adenocarcinoma is poor with therapy and even worse without treatment.
  • The only potentially curative treatment for gastric adenocarcinoma is surgical resection with adequate margins.
  • This report presents a case of gastric adenocarcinoma in a patient who had primary gastric lymphoma treated with partial gastrectomy.
  • The patient is still alive 6 years after diagnosis with no signs of progression despite the fact that no active treatment was given.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22043363.001).
  • [ISSN] 2070-5204
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3191651
  •  go-up   go-down


83. Wang VS, Hornick JL, Sepulveda JA, Mauer R, Poneros JM: Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc; 2009 Apr;69(4):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience.
  • BACKGROUND: The rate of occult adenocarcinoma at esophagectomy in patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) has been reported to be approximately 40%.
  • OBJECTIVE: Our purpose was to determine the rate of submucosal invasive adenocarcinoma in patients undergoing esophagectomy for BE after biopsy diagnosis of HGD or intramucosal carcinoma (IMC).
  • A secondary aim was to identify clinical risk factors for submucosal invasive adenocarcinoma in these patients.
  • MAIN OUTCOME MEASUREMENTS: Submucosal invasive adenocarcinoma at esophagectomy.
  • CONCLUSIONS: The rate of submucosal invasive adenocarcinoma at esophagectomy in BE patients with HGD or IMC on biopsy is much lower than 40%.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / pathology. Esophagectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagoscopy. Female. Humans. Male. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness. Prevalence. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2010 Feb;71(2):429 [20152322.001]
  • (PMID = 19136106.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR: Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol; 2007 Dec;14(12):3460-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum.
  • BACKGROUND: Generally, colorectal and high-grade appendiceal cancers are treated similarly; treatment approach is primarily based on tumor histology and stage of disease.
  • Patients with adenocarcinoma of the lower gastrointestinal tract frequently experience diffuse metastases isolated to liver or peritoneum and have a poor survival.
  • METHODS: Microarray analyses of 20 metastatic tumors from patients with colorectal adenocarcinoma isolated to liver or peritoneum and eight high-grade appendiceal adenocarcinoma metastatic to peritoneum were performed using oligonucleotide microarray.
  • Subsets of genes significantly associated with poor survival were defined, a RET proto-oncogene interacting gene, GOLGA5, was highly predictive for survival in patients with colorectal adenocarcinoma.
  • CONCLUSIONS: These results demonstrate that liver and peritoneal metastases of lower GI adenocarcinoma have distinct gene expression patterns; these distinctions may help in the development of therapies based on site of metastases.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Gene Expression Profiling. Liver Neoplasms / genetics
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / secondary. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899288.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


85. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res; 2008 Feb 1;68(3):759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
  • Here we show that female mice heterozygous for a null Lkb1 allele spontaneously develop highly invasive endometrial adenocarcinomas.
  • This endometrial-specific deletion of the Lkb1 gene provoked highly invasive and sometimes metastatic endometrial adenocarcinomas closely resembling those observed in Lkb1 heterozygotes.
  • This study shows that Lkb1 plays an important role in the malignant transformation of endometrium and that Lkb1 loss promotes a highly invasive phenotype.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Endometrial Neoplasms / genetics. Protein-Serine-Threonine Kinases / deficiency
  • [MeSH-minor] AMP-Activated Protein Kinases. Animals. Cell Polarity / genetics. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Gene Silencing. Genes, Tumor Suppressor. Mice. Multienzyme Complexes / metabolism. Neoplasm Invasiveness

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245476.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCRR NIH HHS / RR / K26RR024196
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


86. Hamano A, Udagawa K, Nomura S, Ishida T: Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component. Scand J Urol Nephrol; 2006;40(1):75-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component.
  • Histological examination of the transurethral resection specimens revealed adenocarcinoma with small foci of squamous and transitional cell carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452061.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


87. Michienzi S, Bucci B, Verga Falzacappa C, Patriarca V, Stigliano A, Panacchia L, Brunetti E, Toscano V, Misiti S: 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy. J Endocrinol; 2007 May;193(2):209-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
  • The pancreatic adenocarcinoma is an aggressive and devastating disease, which is characterized by invasiveness, rapid progression, and profound resistance to actual treatments, including chemotherapy and radiotherapy.
  • At the moment, surgical resection provides the best possibility for long-term survival, but is feasible only in the minority of patients, when advanced disease chemotherapy is considered, although the effects are modest.
  • Three human cell lines hPANC-1, Capan1, and HPAC have been used as experimental models to investigate the T(3) effects on pancreatic adenocarcinoma cell proliferation.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470512.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Thyroid Hormone; 06LU7C9H1V / Triiodothyronine; 0W860991D6 / Deoxycytidine; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; B76N6SBZ8R / gemcitabine; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Zhang Q, Wojno TH, Fitch SD, Grossniklaus HE: Mucinous eccrine adenocarcinoma of the eyelid: report of 6 cases. Can J Ophthalmol; 2010 Feb;45(1):76-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous eccrine adenocarcinoma of the eyelid: report of 6 cases.
  • OBJECTIVE: To report on patients with mucinous eccrine adenocarcinoma of the eyelid.
  • PARTICIPANTS: Biopsy specimens of 6 patients with eyelid neoplasm were obtained.
  • The pathologic diagnoses were mucinous eccrine adenocarcinomas.
  • CONCLUSIONS: Mucinous eccrine adenocarcinoma is an uncommon adnexal tumour that can involve the eyelid, has low metastasis and mortality, but can be invasive or locally recur.
  • Mohs micrographic surgery is a recommended treatment of mucinous eccrine adenocarcinoma of the eyelid.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2002 Aug;28(8):751-4;discussion 754 [12174073.001]
  • [Cites] Z Hautkr. 1974 Nov 15;49(22):963-74 [4141541.001]
  • [Cites] Cancer. 1977 Mar;39(3):1055-63 [199341.001]
  • [Cites] Cancer. 1979 Nov;44(5):1757-68 [227576.001]
  • [Cites] Am J Dermatopathol. 1985 Oct;7(5):461-9 [3004247.001]
  • [Cites] Can J Ophthalmol. 1988 Feb;23(1):17-21 [2832041.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Jan-Feb;22(1):30-5 [16418662.001]
  • [Cites] Am J Dermatopathol. 1995 Oct;17(5):494-8 [8599456.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1125-31 [9737246.001]
  • [Cites] Aust N Z J Ophthalmol. 1999 Feb;27(1):71-3 [10080342.001]
  • [Cites] Dermatol Surg. 1999 Jul;25(7):566-8 [10469115.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):865-80 [13000598.001]
  • [Cites] Br J Cancer. 1952 Dec;6(4):363-8 [13032306.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2099-104 [1327486.001]
  • (PMID = 20130716.001).
  • [ISSN] 1715-3360
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY006360; None / None / / P30 EY006360-25; United States / NEI NIH HHS / EY / P30 EY006360-25
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS239412; NLM/ PMC2992875
  •  go-up   go-down


89. Brock M, Martin W, Sommerer F, Noldus J: [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?]. Urologe A; 2009 Jul;48(7):770-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].
  • [Transliterated title] Das duktale Adenokarzinom der Prostata mit Blasenhalsinfiltration. Heilung durch radikale Zystektomie und antiandrogene Therapie?
  • Ductal adenocarcinoma of the prostate is a rare entity.
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Urol. 2008 Jan;5(1):55-8 [18185514.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):302-9 [16891207.001]
  • [Cites] Cancer. 2007 May 15;109(10):2011-5 [17420979.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] BJU Int. 2008 Nov;102(10):1369-74 [18793296.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • (PMID = 19352617.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


90. Agarwal B, Ludwig OJ, Collins BT, Cortese C: Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Serial analysis of gene expression has helped identify several proteins that are expressed differentially in pancreatic cancer and are highly sensitive and specific for pancreatic adenocarcinoma.
  • RESULTS: In resection specimens, the majority of pancreatic adenocarcinomas expressed all 5 markers but fascin, maspin, and carcinoembryonic antigen-related cell adhesion molecule 6 also were expressed abnormally in normal pancreata and in chronic pancreatitis.
  • In cases requiring a second cytologic consultation, a combined evaluation of cytologic morphology and immunostaining had 90% accuracy for a pancreatic adenocarcinoma diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cell Biology. Pancreatic Neoplasms / diagnosis. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081530.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


91. Lawrence B, Findlay M: Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol; 2010 Mar;2(2):85-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for metastatic pancreatic adenocarcinoma.
  • Systemic treatment of metastatic pancreatic adenocarcinoma achieves only modest benefits, with evidence indicating a survival advantage with 5-fluorouracil (5-FU) over best supportive care alone, and further advantage of single-agent gemcitabine over 5-FU.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):648-53 [11916546.001]
  • [Cites] Oncology. 2002;62(3):223-7 [12065869.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):97-104 [12488300.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1180-4 [12698181.001]
  • [Cites] Invest New Drugs. 1992 Aug;10(3):201-4 [1385353.001]
  • [Cites] Cancer Invest. 2003;21(4):489-96 [14533437.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):474-7 [14998851.001]
  • [Cites] Chemotherapy. 2004 Jun;50(3):127-32 [15282439.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2077-81 [15341982.001]
  • [Cites] Invest New Drugs. 2005 Oct;23(5):489-93 [16133801.001]
  • [Cites] Invest New Drugs. 1990 Feb;8(1):77-80 [2188928.001]
  • [Cites] Cancer. 1990 May 15;65(10):2207-12 [2189551.001]
  • [Cites] Br J Surg. 1990 Jul;77(7):725-30 [2200555.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):29-33 [2934124.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1794-8 [2946815.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):467-9 [7977161.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1556-60 [8137263.001]
  • [Cites] Am J Clin Oncol. 1994 Apr;17(2):166-9 [8141110.001]
  • [Cites] Eur J Cancer. 1993;29A(2):203-4 [8422283.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):379-82 [8431370.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):101-5 [8554969.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):54-7 [8570132.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):307-10 [8638548.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):347-53 [8805925.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1822-3 [8983300.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1797-802 [10468299.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3486-92 [10999733.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4441-7 [16983112.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1450-3 [11100374.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):875-8 [11462946.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):570-4 [11914932.001]
  • [Cites] Br J Surg. 2001 May;88(5):662-8 [11350436.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3447-55 [11481349.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):160-4 [11773165.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):497-501 [12189543.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):580-5 [12649105.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1301-6 [12663718.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2334-40 [14556925.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Cancer Invest. 2004;22(5):688-96 [15581049.001]
  • [Cites] Cancer Invest. 2004;22(5):706-12 [15581051.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4944-50 [15611509.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):645-50 [15646530.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Oncology. 2005;68(2-3):171-8 [16006754.001]
  • [Cites] Oncology. 2005;68(4-6):299-305 [16020956.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1654-61 [16085692.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):189-94 [16133790.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):785-91 [16508631.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1107-15 [16622436.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Mar;30(3):357-63 [16633299.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):301-5 [16634534.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1096-102 [16641168.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1575-9 [16721372.001]
  • [Cites] Pancreatology. 2006;6(5):454-63 [16847383.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):587-92 [16909140.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):82-7 [17030546.001]
  • [Cites] Am J Clin Oncol. 2007 Feb;30(1):26-31 [17278891.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2212-7 [17538165.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jul;37(7):515-20 [17675286.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):47-52 [18181045.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):965-9 [1833042.001]
  • [Cites] Am J Clin Oncol. 2008 Apr;31(2):157-62 [18391600.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9 [18398614.001]
  • [Cites] Oncology. 2007;73(3-4):221-7 [18424886.001]
  • [Cites] Lancet. 2008 Jun 21;371(9630):2101-8 [18514303.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3695-701 [18669454.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):322-5 [8422624.001]
  • [Cites] Invest New Drugs. 1996;13(4):355-8 [8824356.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1358-62 [9849417.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3244-8 [10626195.001]
  • [Cites] Oncology. 2000 Apr;58(3):215-8 [10765123.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2505-11 [10861426.001]
  • [Cites] Invest New Drugs. 2000 Aug;18(3):269-73 [10958597.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):535-7 [10027326.001]
  • [Cites] Clin Ter. 1998 Sep-Oct;149(5):351-5 [10052247.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J BUON. 2008 Jul-Sep;13(3):341-7 [18979547.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):187-95 [18992248.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1592-9 [19237629.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1806-13 [19273710.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3778-85 [19581537.001]
  • (PMID = 21789129.001).
  • [ISSN] 1758-8359
  • [Journal-full-title] Therapeutic advances in medical oncology
  • [ISO-abbreviation] Ther Adv Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3126009
  • [Keywords] NOTNLM ; adenocarcinoma / antineoplastic agents / chemotherapy / metastatic therapeutics / pancreas / pancreatic neoplasms
  •  go-up   go-down


92. Chen YR: Chimeric mouse models for lung adenocarcinomas. Future Oncol; 2010 Jun;6(6):901-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimeric mouse models for lung adenocarcinomas.
  • Evaluation of: Zhou Y, Rideout WM 3rd, Zi T et al.: Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol.


93. Lassalle S, Hofman V, Marius I, Gavric-Tanga V, Brest P, Havet K, Butori C, Selva E, Santini J, Mograbi B, Hofman P: Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid; 2009 Nov;19(11):1239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: With the advent of the formaldehyde standard law in France, and because of the impact of new methods for diagnosis and prognosis in pathology, formalin replacement in surgical pathology laboratories is currently being discussed in France.
  • The objective of this study was to compare formalin substitute fixation with formalin fixation and cryoconservation of tissues from several benign and malignant thyroid pathologies with respect to morphology, antigenicity, and nucleic acid (RNA, DNA, microRNA) integrity.
  • METHODS: Calibrated specimens (200 mg, 1 cm(2) each) from four conventional papillary thyroid carcinomas, four follicular variant of papillary thyroid carcinomas, three minimally invasive follicular carcinomas, four thyroid adenomas, five thyroid nodular hyperplasias, and five normal thyroid tissues were fixed for 6, 12, or 24 hours, in different fixatives (formalin, Glyo-Fixx, FineFIX, ExcellPlus, RCL2) at room temperature or at 4 degrees C.

  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888862.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 0 / Nucleic Acids
  •  go-up   go-down


94. Wolff RA, Varadhachary GR, Evans DB: Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol; 2008 Oct;15(10):2773-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress.
  • Since then, oncologists have debated whether chemotherapy, chemoradiation, or both is optimal adjuvant therapy after pancreatectomy for ductal adenocarcinoma of the pancreas; no global consensus has emerged.
  • This is the only way to ensure that patients who receive adjuvant therapy are actually receiving therapy for radiographically occult possible microscopic disease, rather than therapy for incompletely resected locally advanced disease or early postoperative metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612703.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 67
  •  go-up   go-down


95. Dutsch-Wicherek M, Lazar A, Tomaszewska R: The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma. Cancer Microenviron; 2010;4(1):13-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma.
  • The aim of the present study has been to evaluate the role of RCAS1 in creating the suppressive tumor microenvironment in cases of parotid adenocarcinoma.
  • The tissue samples of salivary gland adenocarcinomas and their stroma and the palatine tonsils which constituted the reference tissue sample group were obtained during routine surgical procedures.
  • A statistically significantly higher RCAS1 immunoreactivity level was found in the adenocarcinoma tissue samples in comparison to that found in the stromal tissue samples.
  • A statistically significantly higher RCAS1 immunoreactivity was also identified in the adenocarcinoma tissue samples derived from patients who had lymph node metastases in comparison to patients without such metastases.
  • The infiltration of CD68-positive cells was significantly stronger in the adenocarcinoma and stromal tissue slides than in the reference group tissue slides; moreover, the infiltration was a good deal more prominent in the stromal tissue than in the adenocarcinoma tissue.
  • Additionally, the infiltration of CD3- and CD25-positive cells was more prominent in the reference tissue slides than in the adenocarcinoma and stromal tissue slides, and was stronger in the adenocarcinoma tissue than in the stromal tissue.
  • Furthermore, the infiltration of Foxp3-positive cells was seen exclusively in the stroma whereas it was not even detected in the adenocarcinoma tissue.
  • The present study demonstrates that RCAS1 expression by both tumor cells and tumor-associated macrophages may participate in creating the immunosuppressive microenvironment in parotid gland adenocarcinoma, thus promoting tumor development as well as metastases.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jul 15;98(2):313-21 [11435298.001]
  • [Cites] J Immunol. 1996 May 1;156(9):3486-92 [8617977.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Gastric Cancer. 2002;5(4):220-7 [12491080.001]
  • [Cites] Pancreas. 2003 Jan;26(1):49-55 [12499917.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Cancer Sci. 2004 Mar;95(3):260-5 [15016327.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):365-73 [15813909.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):189-98 [16112176.001]
  • [Cites] BMC Immunol. 2006;7:4 [16551346.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):924-31 [16842844.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):549-54 [17211709.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):191-203 [17587825.001]
  • [Cites] Am J Reprod Immunol. 2008 Mar;59(3):266-75 [18275520.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Gynecol Obstet Invest. 2009;67(3):195-201 [19122463.001]
  • [Cites] BMC Cancer. 2009;9:35 [19175908.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):838-43 [19574770.001]
  • [Cites] BMC Immunol. 2010;11:10 [20214821.001]
  • [Cites] J Natl Cancer Inst. 1990 Mar 7;82(5):361-70 [2406452.001]
  • [Cites] J Immunol. 1987 Jun 1;138(11):4004-11 [3108380.001]
  • [Cites] Clin Exp Immunol. 1995 Oct;102(1):159-66 [7554383.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1275-82 [7914469.001]
  • [Cites] Hum Immunol. 1997 Aug-Sep;56(1-2):39-48 [9455492.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • [Cites] Acta Biochim Pol. 2003;50(4):1187-94 [14740005.001]
  • [Cites] Liver Int. 2006 Apr;26(3):385-7 [16584404.001]
  • [Cites] Can J Gastroenterol. 2006 Sep;20(9):593-6 [17001401.001]
  • [Cites] Oncol Rep. 2007 Mar;17(3):623-8 [17273743.001]
  • [Cites] J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83 [20061007.001]
  • [Cites] Am J Reprod Immunol. 2010 Mar 1;63(3):181-8 [20085563.001]
  • [Cites] Immunol Today. 1990 Apr;11(4):113-5 [2187466.001]
  • [Cites] Lab Invest. 1984 Dec;51(6):635-42 [6209469.001]
  • [Cites] Science. 1983 Apr 8;220(4593):210-2 [6828888.001]
  • [Cites] Immunol Today. 1993 Jun;14(6):264-70 [8397768.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • (PMID = 21505558.001).
  • [ISSN] 1875-2284
  • [Journal-full-title] Cancer microenvironment : official journal of the International Cancer Microenvironment Society
  • [ISO-abbreviation] Cancer Microenviron
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3047626
  • [Keywords] NOTNLM ; RCAS1-positive macrophages / Salivary gland adenocarcinoma / Tumor microenvironment
  •  go-up   go-down


96. Tepper JE: Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? Gastrointest Cancer Res; 2008 Jul;2(4 Suppl):S2-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma?
  • There have been very few treatment-related studies specifically addressing adenocarcinomas of the gastroesophageal junction (GEJ).
  • Studies addressing esophageal cancer have a larger percentage of patients with GEJ adenocarcinomas than do the primary gastric trials.
  • Combining all three treatment modalities, surgery, radiation therapy, and chemotherapy, is likely to produce the best overall outcomes for patients with this disease, which is rapidly increasing in incidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):739-44 [2508737.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1249-54 [6491703.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • (PMID = 19343142.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2661553
  •  go-up   go-down


97. Götz R: Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int; 2008;8:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutational activation of protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how these two pathways interconnect is only poorly understood.
  • Mouse models of human lung adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to formation of adenomas or adenocarcinomas that lacked metastatic potential.
  • Conditional genetic abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization (angiogenic switch), progression to invasive adenocarcinoma and micrometastasis.
  • I will discuss potential routes to nuclear beta-catenin signalling in cancer and how nuclear beta-catenin may epigenetically alter the plasticity of tumour cells during malignant progression.

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1858-62 [8127895.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):883-9 [8806677.001]
  • [Cites] Histol Histopathol. 1996 Apr;11(2):463-83 [8861769.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1521-6 [9118033.001]
  • [Cites] Cell. 1997 Sep 5;90(5):871-82 [9298899.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6166-70 [9497337.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5762-70 [9742093.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):687-99 [10037790.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):406-11 [10425198.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36734-40 [10593980.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):185-90 [10775035.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):813-8 [11259097.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20436-43 [11279024.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Curr Biol. 2005 Nov 22;15(22):1989-97 [16303557.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):729-39 [16332724.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2279-86 [16489032.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):606-13 [16699315.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Development. 2006 Jul;133(13):2455-65 [16735479.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2261-71 [16894562.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Methods Enzymol. 2006;419:285-321 [17141060.001]
  • [Cites] Genes Dev. 2007 Feb 15;21(4):379-84 [17299132.001]
  • [Cites] Cell. 2007 Feb 23;128(4):735-45 [17320510.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4933-9 [17510423.001]
  • [Cites] Cell. 2007 Jun 1;129(5):957-68 [17540175.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):318-24 [17554336.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):445-51 [17597761.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):260-2 [17637646.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Arch Toxicol. 1991;65(2):81-94 [1711838.001]
  • [Cites] Exp Cell Res. 1967 Apr;46(1):144-54 [6025276.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):461-71 [7542250.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4553-61 [7623846.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Mar 28;208(3):1067-72 [7702605.001]
  • [Cites] Cell Adhes Commun. 1994 Aug;2(4):319-27 [7820535.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1375-80 [7962096.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 30;205(1):73-8 [7999105.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Cell Biol Int. 2007 Apr;31(4):366-73 [17336101.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3113-21 [17496910.001]
  • [Cites] J Pathol. 2007 Jul;212(3):287-94 [17534846.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):145-59 [17692806.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):147-58 [18246411.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):547-53 [11709274.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Mech Dev. 2002 Jul;115(1-2):53-62 [12049767.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):173-82 [12107102.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6297-303 [12414660.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1333-8 [12423687.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2287-97 [12640114.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2268-77 [12727849.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3207-19 [15226396.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):339-49 [15492040.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] APMIS. 2005 Jan;113(1):54-7 [15676015.001]
  • [Cites] Development. 2005 Mar;132(6):1363-74 [15716345.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):55-70 [18371336.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Annu Rev Physiol. 2004;66:601-23 [14977415.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] J Biol. 2004;3(3):11 [15186480.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2225-30 [15371335.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):639-47 [15519853.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9719-26 [16266992.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Cell. 2005 Dec 2;123(5):903-15 [16325583.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):283-9 [16397241.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):399-410 [16481469.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Development. 2006 May;133(9):1611-24 [16613830.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1394-404 [16751178.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • (PMID = 18492263.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2427011
  •  go-up   go-down


98. Xu J, Liang Z, Hao S, Zhu L, Ashish M, Jin C, Fu D, Ni Q: Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging; 2009 Nov;34(6):759-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging.
  • Thus, in lesions of the tissues of the pancreas, this offers to increase the accuracy of CT diagnosis.
  • In this study, our aim was to explore the perfusion characteristics of normal pancreas and pancreatic adenocarcinoma.
  • METHODS: Dynamic 64-slice helical CT was conducted in 36 patients with non-pancreatic disease and in 40 patients with histopathologically proven pancreatic adenocarcinoma.
  • BF, BV, and PS values of the tumor tissue of pancreatic adenocarcinoma decreased significantly compared to normal pancreas (P < 0.05).
  • A significant decrease of BF, BV, and PS was observed in pancreatic adenocarcinoma.
  • Dynamic 64-slice helical CT with perfusion imaging should be considered a potential modality to increase the accuracy of CT diagnosis for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672566.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


99. Hisatomi M, Asaumi J, Yanagi Y, Unetsubo T, Maki Y, Murakami J, Matsuzaki H, Honda Y, Konouchi H: Diagnostic value of dynamic contrast-enhanced MRI in the salivary gland tumors. Oral Oncol; 2007 Oct;43(9):940-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (a) The salivary gland tumors were categorized into three CI curve types according to Tmax and WR300; Pleomorphic adenoma; Tmax > 210 s and WR300 < 10%, Warthin tumor; Tmax < 60 s and WR300 > 40%, and malignant tumor; 60s < Tmax < 210 s and 10% < WR300 < 30%;.
  • (b) On the basis of the relationship between Tmax and CImax or WR, all pleomorphic adenomas were successfully differentiated from Warthin tumor lesions.
  • Of the 20 pleomorphic adenomas, 18 (90.0%) were successfully differentiated from malignant tumors.
  • All Warthin tumor lesions were successfully differentiated from pleomorphic adenomas and malignant tumors.
  • Of 12 the malignant tumors, 11 (91.7%) were successfully differentiated from pleomorphic adenomas.
  • All malignant tumors were successfully differentiated from Warthin tumors.
  • [MeSH-major] Gadolinium DTPA. Image Processing, Computer-Assisted. Magnetic Resonance Imaging / methods. Radiopharmaceuticals. Salivary Gland Neoplasms / diagnosis
  • [MeSH-minor] Adenolymphoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Parotid Neoplasms / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257881.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


100. Caruso S, Marrelli D, Pedrazzani C, Neri A, Mazzei MA, Onorati M, Corso G, Cerullo G, Roviello F: A rare case of primary small bowel adenocarcinoma with intussusception. Tumori; 2010 Mar-Apr;96(2):355-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of primary small bowel adenocarcinoma with intussusception.
  • We report the case of a 51-year-old man presenting with jejunal intussusception due to a primary adenocarcinoma.
  • Histological examination of the specimen resulted in a diagnosis of a primary adenocarcinoma of the small bowel.
  • [MeSH-major] Adenocarcinoma / complications. Intussusception / etiology. Jejunal Diseases / etiology. Jejunal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572601.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement